<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10897011</article-id><article-id pub-id-type="pmcid-ver">PMC10897011.1</article-id><article-id pub-id-type="pmcaid">10897011</article-id><article-id pub-id-type="pmcaiid">10897011</article-id><article-id pub-id-type="pmid">38415258</article-id><article-id pub-id-type="doi">10.3389/fimmu.2024.1347181</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Advances in reprogramming of energy metabolism in tumor T cells</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Xuekai</surname><given-names initials="L">Liu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2649935"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Yan</surname><given-names initials="S">Song</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1505359"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jian</surname><given-names initials="C">Chu</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2538065"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yifei</surname><given-names initials="S">Song</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xinyue</surname><given-names initials="W">Wu</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2649845"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wenyuan</surname><given-names initials="Z">Zhang</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2649928"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Shuwen</surname><given-names initials="H">Han</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/937718"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Xi</surname><given-names initials="Y">Yang</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1632594"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Clinical Laboratory, Aerospace Center Hospital</institution>, <addr-line>Beijing</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Department of Medical Oncology, Huzhou Central Hospital, Affiliated Central Hospital Huzhou University</institution>, <addr-line>Huzhou</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Department of Gastroenterology, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University (Huzhou Central Hospital)</institution>, <addr-line>Huzhou</addr-line>, <country>China</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Department of Key Laboratory of Multiomics Research and Clinical Transformation of Digestive Cancer</institution>, <addr-line>Huzhou</addr-line>, <country>China</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Department of Gynecology, Heyuan Hospital of Traditional Chinese Medicine</institution>, <addr-line>Heyuan</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Lewis Zhichang Shi, University of Alabama at Birmingham, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Ming Yi, Zhejiang University, China</p><p>Nicole M. Chapman, St. Jude Children&#8217;s Research Hospital, United States</p></fn><corresp id="fn001">*Correspondence: Zhang Wenyuan, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:zhangwenyuan1976@163.com">zhangwenyuan1976@163.com</email>; Han Shuwen, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:shuwenhan985@163.com">shuwenhan985@163.com</email>; Yang Xi, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:yangxi19910601@126.com">yangxi19910601@126.com</email></corresp><fn fn-type="equal" id="fn003"><p>&#8224;These authors have contributed equally to this work and share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>13</day><month>2</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">454094</issue-id><elocation-id>1347181</elocation-id><history><date date-type="received"><day>30</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>29</day><month>1</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>27</day><month>02</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-28 17:25:10.093"><day>28</day><month>02</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 Xuekai, Yan, Jian, Yifei, Xinyue, Wenyuan, Shuwen and Xi</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Xuekai, Yan, Jian, Yifei, Xinyue, Wenyuan, Shuwen and Xi</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-15-1347181.pdf"/><abstract><p>Cancer is a leading cause of human death worldwide, and the modulation of the metabolic properties of T cells employed in cancer immunotherapy holds great promise for combating cancer. As a crucial factor, energy metabolism influences the activation, proliferation, and function of T cells, and thus metabolic reprogramming of T cells is a unique research perspective in cancer immunology. Special conditions within the tumor microenvironment and high-energy demands lead to alterations in the energy metabolism of T cells. In-depth research on the reprogramming of energy metabolism in T cells can reveal the mechanisms underlying tumor immune tolerance and provide important clues for the development of new tumor immunotherapy strategies as well. Therefore, the study of T cell energy metabolism has important clinical significance and potential applications. In the study, the current achievements in the reprogramming of T cell energy metabolism were reviewed. Then, the influencing factors associated with T cell energy metabolism were introduced. In addition, T cell energy metabolism in cancer immunotherapy was summarized, which highlighted its potential significance in enhancing T cell function and therapeutic outcomes. In summary, energy exhaustion of T cells leads to functional exhaustion, thus resulting in immune evasion by cancer cells. A better understanding of reprogramming of T cell energy metabolism may enable immunotherapy to combat cancer and holds promise for optimizing and enhancing existing therapeutic approaches.</p></abstract><kwd-group><kwd>metabolic reprogramming</kwd><kwd>T cells</kwd><kwd>immunotherapy</kwd><kwd>immune microenvironment</kwd><kwd>energy metabolism</kwd></kwd-group><funding-group><funding-statement>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Traditional Chinese Medicine Research Project of Guangdong Provincial Chinese Medicine Bureau (No.20231334), Zhejiang Medical and Health Technology Project (No.2023KY1178), and Public Welfare Technology Application Research Program of Huzhou (No.2023GZ82).</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="0"/><equation-count count="0"/><ref-count count="133"/><page-count count="11"/><word-count count="5265"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>T Cell Biology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Cancer is one of the leading causes of death globally and affects a large number of people. Cancer treatment has progressed from traditional approaches, such as surgical resection, radiotherapy, and chemotherapy, to immunotherapies, such as immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cells (CAR-T cells), and cytokine therapies (<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B3" ref-type="bibr">3</xref>). Immunotherapy refers to the use of the body&#8217;s immune system to treat cancer. Different from traditional therapies, immunotherapy employs a variety of immune cells (such as T cells, natural killer (NK) cells, and dendritic cells), cytokines, and chemokines [such as C-X-C motif chemokine ligand 12 (CXCL12), CXCL10, and C-C motif chemokine ligand 5 (CCL5)] to remodel the tumor microenvironment (TME), which can yield potent effects and aid in preventing cancer recurrence (<xref rid="B4" ref-type="bibr">4</xref>). The advent of immunotherapy has sparked a paradigm shift in the standards and approaches of cancer treatment. Although immunotherapy is a promising treatment, a significant proportion of patients exhibit limited or no response to immunotherapy (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). Therefore, a better understanding of the key components of TME may help refine current immunotherapeutic strategies.</p><p>TME consists of a heterogeneous milieu of tumor and immune cells, and has been shown to participate in tumor progression and affect immunotherapy response (<xref rid="B7" ref-type="bibr">7</xref>). As an important component of TME, T lymphocytes (T cells) are not only key cells of cellular immunity, but also an important focus in anti-tumor responses (<xref rid="B8" ref-type="bibr">8</xref>). T cells derived from the bone marrow lymphoid stem differentiate into mature cells in the thymus. Na&#239;ve T cells can be divided into two main subsets, namely CD4+ and CD8+ T cells, which have patrol and surveillance functions (<xref rid="B9" ref-type="bibr">9</xref>). Once activated by antigen-presenting cells (APCs), CD4+ T cells can rapidly differentiate into different subtypes: CD4+ effector T cell (Teff) exhibits anti-tumor activity, and regulatory T cell (Treg) has immunosuppressive and tumor-promoting effects (<xref rid="B10" ref-type="bibr">10</xref>). CD8+ T cells can differentiate into CD8+ Teff cells (also known as cytotoxic T cells) and memory T cells (Tmem) (<xref rid="B11" ref-type="bibr">11</xref>). CD8+ Teff cells directly kill tumor cells by promoting apoptosis and cytokine secretion. Tmem cells can recognize immune memory antigens and rapidly exert their tumor cell-killing function, which is crucial for long-term survival of the host. In the final stages of tumor development, CD8+ T cells are active and exert anti-tumor effects (<xref rid="B9" ref-type="bibr">9</xref>). In addition, T cells participate in the immune regulation of almost all cancers, including colorectal cancer (CRC), and are considered as critical determinants of clinical outcomes (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). A range of T cell-based therapies have demonstrated efficacy in inducing complete and long-lasting responses in patients with various cancer types (<xref rid="B14" ref-type="bibr">14</xref>&#8211;<xref rid="B16" ref-type="bibr">16</xref>). The function of immunosuppressive checkpoints in T cells, including programmed cell death protein (PD-1) and cytotoxic T lymphocyte (CTL)-associated protein 4 (CTLA-4), provides a basis for tumor immunotherapy. These checkpoints regulate T cell activity and play a role in preventing excessive immune responses. However, some tumor cells can exploit these checkpoints to evade immune detection and attack (<xref rid="B17" ref-type="bibr">17</xref>&#8211;<xref rid="B19" ref-type="bibr">19</xref>).</p><p>Immune cells share similarities with tumor cells in terms of their involvement in metabolic regulation to maintain cell proliferation and survival (<xref rid="B20" ref-type="bibr">20</xref>). Following activation, T cells may undergo metabolic reprogramming characterized by a switch from oxidative metabolism to aerobic glycolysis, also known as Warburg effect (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). This metabolic shift requires precise metabolic rewiring to enable T cells to fulfill the increased energy requirements for their proliferation and effector functions (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). Chang et&#160;al. suggested that cell can use either mitochondrial metabolism or glycolysis for ATP generation. When glycolysis in T cells is blocked, their ability to produce iinterferon (IFN)-&#947; is impaired, and then anti-tumor immune response is reduced (<xref rid="B23" ref-type="bibr">23</xref>). Therefore, adjusting the metabolic processes and functions of T cells has potential for improving the efficacy of tumor immunotherapy (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Mitochondria are dynamic and interconnected organelles that are core regulators of metabolic reprogramming and play crucial roles in controlling the activation and function of immune cells such as T cells (<xref rid="B26" ref-type="bibr">26</xref>). Ron-Harel et&#160;al. also revealed that during T cell activation, mitochondrial proteome remodeling generates specialized mitochondria with enhanced one-carbon metabolism, which is critical for T cell activation and survival (<xref rid="B27" ref-type="bibr">27</xref>). However, T cell energy metabolism in TME and its effects on tumors have not been comprehensively reported.</p><p>In this review, the recent progress in research on T cell energy metabolic reprogramming is described, including T cell energy metabolism and its role in regulating T cell function, influencing factors, and T cell energy metabolism in cancer immunotherapy. A better understanding of T cell metabolic programming in TME holds promise for enhancing the anti-tumor immune response and improving the efficacy of tumor immunotherapy.</p></sec><sec id="s2"><title>Role in regulating T cell function</title><p>Metabolic reprogramming has recently become a rapidly growing field in tumor research, and it is not limited to tumor cells, but can also occur in immune cells (<xref rid="B28" ref-type="bibr">28</xref>). Among the various immune cells with different functions, T cells are the main cell type that exert anti-tumor effects in the adaptive immune stage (<xref rid="B29" ref-type="bibr">29</xref>). The proliferation and differentiation of T cells are strongly influenced by dynamic changes in their metabolism (<xref rid="B30" ref-type="bibr">30</xref>). T cells in the quiescent phase have low metabolic requirements, and low levels of oxidative phosphorylation (OXPHOS) can meet their growth and survival needs. When they encounter antigens, quiescent T cells are activated and require energy to undergo metabolic reprogramming to support their anti-tumor functions (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). Similar to rapidly proliferating tumor cells, the metabolism of T cells shifts from low levels of OXPHOS to high levels of aerobic glycolysis and glutamine metabolism (<xref rid="B33" ref-type="bibr">33</xref>).</p><p>Mitochondria are the major sites for cellular energy production. Mitochondrial metabolism is the core of the cellular metabolic network, encompassing processes such as OXPHOS, the tricarboxylic acid (TCA) cycle, and amino acid metabolism, all of which occur within the mitochondria (<xref rid="B34" ref-type="bibr">34</xref>). Abnormal levels of reactive oxygen species (ROS) in tumor cells can damage mitochondrial DNA (mtDNA), thereby affecting the normal function of the mitochondrial membrane respiratory chain and adenosine triphosphate (ATP) production system (<xref rid="B35" ref-type="bibr">35</xref>). The rapid increase in ROS accelerates the destruction of mitochondrial function, thus resulting in tumor cells that obtain ATP through glycolysis and metabolic reprogramming (<xref rid="B36" ref-type="bibr">36</xref>). Moreover, prolonged antigen exposure, hypoxia within the TME, or inhibitory signaling can induce various mitochondrial changes in T cells, such as aberrant localization, altered morphology, disrupted structure, and/or perturbed membrane potential (&#916;&#936;m) (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). These modifications are closely linked to functional deterioration, such as suppressed mitochondrial biogenesis, diminished ATP generation, mitochondrial reactive oxygen species (mtROS) accumulation, disrupted mitophagy, and impaired OXPHOS and fatty acid oxidation (FAO) (<xref rid="B26" ref-type="bibr">26</xref>), thereby resulting in an inability to fulfill energy requirements and the occurrence of T cell exhaustion. Mitochondrial morphology controls T cell metabolism and can destroy tumor cells by enhancing T cell recognition. Activated Teff cells possess fragmented mitochondria, whereas Tmem cells maintain the mitochondria in a fused network. By modulating cristae morphology, fusion in Tmem cells regulates the association of the electron transport chain (ETC) complex, which promotes OXPHOS and FAO. Conversely, fission in Teff cells results in expansion of cristae, impairment of ETC efficiency, and preference of aerobic glycolysis (<xref rid="B39" ref-type="bibr">39</xref>). Furthermore, mitochondria contain large amounts of Ca2+ and control the absorption and uptake of calcium ions within the cell. Taken together, these results indicate that mitochondria play a key role in controlling T cell activation and function.</p></sec><sec id="s3"><title>Various pathways associated with T cell energy metabolism</title><sec id="s3_1"><title>Glycolytic pathway</title><p>Mitochondria are hubs of cellular metabolism, including glucose, amino acid, and fatty acid metabolism (<xref rid="B40" ref-type="bibr">40</xref>). As the main pathway of energy metabolism in tumor cells, glycolysis is crucial for the proliferation and functional activities of immune cells (<xref rid="B41" ref-type="bibr">41</xref>). Upon T cell activation, there is a shift in their metabolism from a quiescent state, primarily relying on OXPHOS, to an activated state characterized by increased glycolysis, which allows for the swift production of ATP and metabolic intermediates necessary for cell proliferation and effector molecule synthesis (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). It has been reported that the na&#239;ve T cells rely on OXPHOS to maintain energy requirements, while activated T cells consume a large amount of glucose through aerobic glycolysis to exert anti-tumor effects (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). HIF-1&#945; is required for effector states in CD8+T cells, and the loss of HIF-1&#945; in CD8+T cells reduces tumor invasion and tumor cell killing and alters tumor vascularization (<xref rid="B44" ref-type="bibr">44</xref>). Mitochondrial dysfunction causes redox stress, which inhibits proteasomal degradation of Hypoxia-inducible factor-1&#945; (HIF-1&#945;) and promotes transcription and metabolic reprogramming of Tpex cells to become exhausted T cells (<xref rid="B45" ref-type="bibr">45</xref>). In addition, MYC plays a key role in regulating the response of HIF-1&#945; to hypoxia, and the MYC signaling pathway is uncoupled from the increased transcription of HIF-dependent glycolytic genes in glycolytic flux during hypoxia (<xref rid="B46" ref-type="bibr">46</xref>). In CD4+T cells, the loss of HIF-1&#945; or HIF-1&#945; and HIF-2&#945; also impairs essential functions during antibody response. Glycolysis increases the expression of T helper cytokines, and HIF promotes glycolysis in T helper cells through TCR or cytokine stimulation (<xref rid="B47" ref-type="bibr">47</xref>). Solute carrier (SLC) plays an important physiological function in cells. Increased glucose uptake mediated by GLUT1 and GLUT3 transporters maintains T cell activation and promotes differentiation (<xref rid="B48" ref-type="bibr">48</xref>). After entering the site of inflammation, CD4+ and CD8+ T cell subsets internalize high levels of lactic acid via SLC15A2 and MCT1 (SLC16A1), respectively (<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>). Macintyre AN et&#160;al. &#8216;s findings suggest that Glut1 deficiency leads to impaired glucose uptake and glycolysis within CD4 T cells, thereby reducing the survival and differentiation ability of T effector cells, as well as the ability to induce inflammatory diseases <italic toggle="yes">in vivo</italic>. However, the function of Tregs does not appear to be affected by the Glut1 defect (<xref rid="B48" ref-type="bibr">48</xref>). In addition, metabolites produced during glycolysis also participate in the activation and effector function of T cells through other ways. Teff cells up-regulate specific glycolytic pathways to achieve rapid proliferation and play anti-tumor effect, including aerobic glycolysis, pentose phosphate pathway (PPP), hexosamine biosynthetic pathway (HBP), and TCA cycle support (<xref rid="B51" ref-type="bibr">51</xref>). CD8 T cells are an important part of human adaptive immune response, and changes in glycolysis have important effects on their activation and function. Activation of CD8 T cells by TCR leads to the transfer of cellular metabolic level to glycolysis, while the synergistic stimulation of CD28 further increases the glycolysis level of CD8 T cells to support subsequent proliferation and differentiation (<xref rid="B52" ref-type="bibr">52</xref>). The induction of high glycolytic activity is conducive to the differentiation of CD8 T cells into effector cells, but it can seriously impair the survival ability of Tmem cells (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>).</p></sec><sec id="s3_2"><title>Amino acid metabolic pathway</title><p>In addition to glycolysis, the massive proliferation of activated T cells relies primarily on amino acid metabolism to support protein and nucleotide synthesis (<xref rid="B55" ref-type="bibr">55</xref>). Glutamine metabolism supplies carbon and nitrogen necessary for the synthesis of amino acids, nucleic acids, and lipids. The lack of glutamine inhibits T cell proliferation and cytokine production, which implies that the restoring high levels of glutamine to the TME can enhance T cell killing of tumor cells (<xref rid="B56" ref-type="bibr">56</xref>).</p><p>Besides, arginine is a precursor in the biosynthesis of many macromolecules, including proteins, creatine, and polyamines (<xref rid="B57" ref-type="bibr">57</xref>&#8211;<xref rid="B59" ref-type="bibr">59</xref>). As arginine deprivation can lead to cell cycle arrest, arginine is important for T cell proliferation (<xref rid="B60" ref-type="bibr">60</xref>). Elevated L-arginine levels induced a shift from glycolysis to oxidative phosphorylation in activated T cells and promoted the production of central memory-like cells with higher viability. Intracellular L-arginine concentration can directly affect the metabolic adaptability and viability of T cells, which also reveals the importance of its anti-tumor response (<xref rid="B61" ref-type="bibr">61</xref>).</p><p>The presence of extracellular methionine influences the epigenetic programming responsible for shaping the destiny of CD8+ T cells and synergizes with serine (which can be synthesized internally from glucose or obtained externally) to stimulate one-carbon metabolism (<xref rid="B62" ref-type="bibr">62</xref>&#8211;<xref rid="B64" ref-type="bibr">64</xref>). Lysine catabolism can affect CD8+ T cells to reprogram tumor immunity via histone crotonylation (<xref rid="B65" ref-type="bibr">65</xref>). Amino acids, particularly arginine and leucine, signal to allow TCR-induced mTORC1 activation and subsequent changes in mitochondrial metabolism in Treg cells via RagA/B and Rheb1/2 (<xref rid="B66" ref-type="bibr">66</xref>). SLC1A5 or SLC38A1 cotransports glutamine and leucine exchanged via the SLC7A5-SLC3A2 complex can promote mTORC1 activation through direct and indirect mechanisms, thereby regulating T cell metabolism (<xref rid="B67" ref-type="bibr">67</xref>). Tryptophan is an essential amino acid and factor in determining the strength and effectiveness of T cell responses in TME. Tryptophan can directly activate cytoplasmic transcription factor-aryl hydrocarbon receptor (AhR) by producing kynurenine (Kyn) catalyzed by indoleamine 2,3-dioxygenase (IDO) (<xref rid="B68" ref-type="bibr">68</xref>). T cells can regulate Tumor repopulating cells (TRC) that can induce CD8+ T cells to express PD-1 through Kyn uptake and AhR activation through IDO-Kyn-AhR pathway (<xref rid="B68" ref-type="bibr">68</xref>). Besides, glutaric acid, a key metabolite produced during the breakdown of tryptophan and lysine within T cells, regulates T cell differentiation by altering epigenetic and energy metabolism (<xref rid="B69" ref-type="bibr">69</xref>).</p></sec><sec id="s3_3"><title>Fatty acid metabolic pathway</title><p>Lipids are divided into a variety of subtypes based on their structural/biological characteristics, including fatty acids (FAs), phospholipids, cholesterol, triglycerides, etc. In TME, lipid metabolism, as an important energy source and one of the significant components of cell membrane, is closely related to T cell proliferation and function (<xref rid="B70" ref-type="bibr">70</xref>). T cell senescence driven by malignant tumor cells and TreGs is a common feature in cancer development. Senescent T cells have active glucose metabolism, but their lipid metabolism is unbalanced (<xref rid="B71" ref-type="bibr">71</xref>). Through experiments in mouse models of melanoma and breast cancer, Liu X found that the inhibition of phospholipase A2-IVA can reprogram lipid metabolism of effector T cells and prevent T cell aging. Oxidized cholesterol is enriched in the tumor microenvironment, and oxidized cholesterol inhibits SREPB2 pathway from activating LXR pathway, thus resulting in cholesterol deficiency and T cell dysfunction (<xref rid="B72" ref-type="bibr">72</xref>). Moreover, FAO is involved in the generation and functional maintenance of Tmem cells. Saibil et&#160;al. proved that, as the energy source, FAO enables Tmem cells to respond to antigen stimulation in a timely manner, which is conducive for maintaining the normal function of Tmem mitochondria and long-term cell survival (<xref rid="B73" ref-type="bibr">73</xref>). FAO regulates the balance between Teff and Treg cells (<xref rid="B74" ref-type="bibr">74</xref>). However, it should not be ignored that while Tregs do depend on mitochondrial function, it is not necessarily fatty acid oxidation. For example, Chapman et&#160;al. discovered that mTOR plays an important role in coordinating transcriptional and metabolic programs in activated treg subpopulations, thereby mediating tissue homeostasis processes (<xref rid="B75" ref-type="bibr">75</xref>). Weinberg et&#160;al. demonstrated that Treg cells require mitochondrial complex III to maintain immune regulatory gene expression and suppressive function (<xref rid="B76" ref-type="bibr">76</xref>). Furthermore, mitochondrial transcription factor A (Tfam) is essential for mitochondrial respiration and the control of mitochondrial DNA replication, transcription, and packaging. The loss of Tfam in Treg affects Treg homing and stability, thus leading to tissue inflammation in colitis, but enhances tumor rejection, which reveals the key role of TFAM-mediated mitochondrial respiration in regulating inflammation and anti-tumor immunity in Tregs (<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B77" ref-type="bibr">77</xref>). Saravia et&#160;al. revealed that the transcriptional regulatory factor c-Myc can coordinate immune homeostasis by coordinating treg accumulation, transitional activation, and metabolic programming (<xref rid="B78" ref-type="bibr">78</xref>). However, in fact, several recent studies showed that Cpt1a is dispensable for Treg generation or function <italic toggle="yes">in vivo</italic>. For example, Raud et&#160;al. illustrated that the ACC2/Cpt1a axis is largely indispensable for the formation of Teff, Tmem or Tregcell, and the effects of etomoxil on T cell differentiation and function are independent of Cpt1a expression (<xref rid="B79" ref-type="bibr">79</xref>). This finding provides data support that metabolic pathways other than LC-FAO can promote Tmemor treg differentiation. Besides, Treg-specific deletion of Cox10, rather than FAO&#8217;s rate-limiting enzyme Cpt1a, has been confirmed to promote oxidative phosphorylation, thereby leading to impaired treg function and maturation (<xref rid="B78" ref-type="bibr">78</xref>). What&#8217;s more, the lipid metabolism reprogramming of CD8+ T cells can affect the biology of tumor cells (<xref rid="B80" ref-type="bibr">80</xref>). Yang W et&#160;al. identified cholesterol esterification enzyme (ACAT1) as a metabolic checkpoint that regulates tumor immune response, and inhibition of its activity can increase the level of free cholesterol on CD8+ T cell membrane, thereby enhancing the tumor-killing ability of CD8+ T cells (<xref rid="B81" ref-type="bibr">81</xref>). The main mechanism is that the plasma membrane cholesterol level of CD8+ T cells increases significantly, which helps the efficient formation of T cell antigen receptor clusters and immune synapses. Moreover, studies have confirmed that the combination of ACAT inhibitor Avasimibe and PD-1 antibody can further improve the effectiveness of tumor immunotherapy. Moreover, Fan J et&#160;al. found that mitochondrial ACAT1 and SIRT3 are upstream acetyltransferase and deacetylase of PDHA1 and PDP1, respectively, and knockdown of ACAT1 can weaken tumor growth (<xref rid="B82" ref-type="bibr">82</xref>). These studies suggest the potential of ACAT1 as a target for anti-cancer drugs. Overall, different states of T cells are controlled by multiple metabolic programs (<xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>). The metabolic reprogramming of T cells is an essential component of the immune response. Understanding and manipulating T cell energy metabolism has significant implications for developing novel immunotherapies and enhancing immune responses against tumors.</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>T cell hypermetabolism includes glucose metabolism, amino acid metabolism, and lipid metabolism.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-15-1347181-g001.jpg"/></fig></sec></sec><sec id="s4"><title>Various factors associated with T cell energy metabolism</title><p>Research has shown that various factors associated with T cell energy metabolism have significant impacts on T cell function. Herein, T cell energy metabolism-related factors are shown in <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>.</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>Various factors associated with T cell energy metabolism.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-15-1347181-g002.jpg"/></fig><sec id="s4_1"><title>Hypoxia</title><p>Hypoxia in the TME has a unique two-sided effect on immune cell function (<xref rid="B85" ref-type="bibr">85</xref>). Under hypoxic conditions, multiple oxygen-independent signals, including those present in T cells, increased hypoxia-inducible factor (HIF) activity (<xref rid="B86" ref-type="bibr">86</xref>). After activation via oxygen-independent pathways, T cells depend on HIFs to sustain glycolytic metabolism. For instance, Oestreich et&#160;al. reported that following T cell activation, decreased interleukin (IL)-2 exposure lead to elevated B-cell lymphoma 6 (Bcl-6) expression, which directly inhibited glycolytic genes regulated by HIF-1&#945; and c-myc. This mechanism suppresses glycolytic metabolism and effector function, and consequently influences the fate of T cells in a microenvironment-dependent manner (<xref rid="B87" ref-type="bibr">87</xref>). A previous investigation on Foxp3-regulatory CD4+ T cells revealed the involvement of HIF-1&#945; in maintaining a glycolytic metabolic shift in CD4+ T cells, when it was activated and cultured <italic toggle="yes">in vitro</italic> with IL-27 (<xref rid="B88" ref-type="bibr">88</xref>), which suggested the crucial role of HIF-1&#945; in modulating CD4+ T cell metabolism. The HIF-1&#945; expression in CD8+ T cells promotes glycolytic metabolism, thus leading to enhanced proliferation and effector functions of CD8+ T cells (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B89" ref-type="bibr">89</xref>). Compared with normoxic T cells, hypoxic CD8+ T cells increased the packaging of granzyme B into particles and cleared B16 tumors more effectively in mice (<xref rid="B90" ref-type="bibr">90</xref>). This adaptive metabolic transformation and functional enhancement contribute to the anti-tumor effects of CD8+ T cells in a hypoxic environment. In a CRC cell model, it has been observed that hypoxia enhances the CD8+ T cell activity and promotes IFN-&#947; expression (<xref rid="B91" ref-type="bibr">91</xref>).</p></sec><sec id="s4_2"><title>Lactate accumulation</title><p>To achieve &#8220;metabolic equilibrium,&#8221; tumor cells not only consume important nutrients but also produce toxic metabolic waste to further impact the differentiation of CD8+ T cells and impair T cell function. Among these, lactate accumulation has attracted considerable attention. Owing to the aerobic glycolytic activity of tumor cells, lactate accumulates in the TME, and high lactate concentrations directly regulate the effector function of CD8+ T cells (<xref rid="B92" ref-type="bibr">92</xref>). Activated T cells primarily produce ATP and biomacromolecules via aerobic glycolysis. To maintain a high glycolytic rate, CD8+ T cells export lactate through Monocarboxylate Transporter 1 (MCT1). The transport activity of MCT1 is mainly regulated by the lactate concentration gradient in the cell membrane. However, lactate accumulation in the TME disrupts MCT1-mediated lactic acid export from CD8+ T cells, and further induces an inhibitory tumor-infiltrating (TIL) CD8+ phenotype (<xref rid="B92" ref-type="bibr">92</xref>). Robert et&#160;al. also demonstrated that the build-up of lactic acid generated by CRC cell metabolism and the resulting acidic environment could repress glycolysis and impair T cell functionality (<xref rid="B93" ref-type="bibr">93</xref>). Additionally, lactic acid can induce the upregulation of CXCL10, which facilitates the attraction of CD4+ T cells to the metastatic site and triggers receptor activator of nuclear factor-&#954;B-ligand (RANKL) production, thereby promoting CRC bone metastasis (<xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B95" ref-type="bibr">95</xref>).</p></sec><sec id="s4_3"><title>Gut microbiota</title><p>Dysregulation of the gut microbiota is a crucial factor in both cancer onset and immune system modulation, which ultimately affectes the efficacy of immunotherapy (<xref rid="B96" ref-type="bibr">96</xref>). In mouse models, a microbial mixture could boost anticancer immunity by stimulating the production of IFN-&#947;-producing cytotoxic T cells (CTCs) within tumor tissues (<xref rid="B97" ref-type="bibr">97</xref>). <italic toggle="yes">Escherichia coli, Firmicutes, and Bacteroides fragilis</italic> have been found to promote the migration of T cells into CRC tissues by upregulating the expression of chemokines involved in T cell recruitment (<xref rid="B98" ref-type="bibr">98</xref>). However, colibactin-producing <italic toggle="yes">Escherichia coli</italic> can impair the infiltration of CD3+ and CD8+ T cells into the CRC, thus resulting in tumor resistance to immunotherapy (<xref rid="B99" ref-type="bibr">99</xref>). Moreover, the colonization of Bifidobacterium in the intestine can result in changes in the composition of the gut microbiota and increase the suppressive function of Treg cells by promoting mitochondrial activity, which indicates the crucial role of gut microbiota in the metabolic reprogramming of T cells (<xref rid="B100" ref-type="bibr">100</xref>).</p><p>What&#8217;s more, the gut microbiota generates multiple metabolites that can interact with host tissues and the immune system, which exertes a significant influence on T cell development and function (<xref rid="B101" ref-type="bibr">101</xref>, <xref rid="B102" ref-type="bibr">102</xref>). Intestinal immune homeostasis can be maintained by Treg cells, and microbial bile acid metabolites are vital for generating colonic Treg cells and suppressing intestinal inflammation (<xref rid="B103" ref-type="bibr">103</xref>&#8211;<xref rid="B106" ref-type="bibr">106</xref>). Bacterial production of short-chain fatty acids (SCFAs), such as butyrate, can alleviate dextran sulfate sodium and clostridium difficile induced colitis by preventing Th17 through activation of SIRT1/mTOR (<xref rid="B107" ref-type="bibr">107</xref>). SCFAs, as the substrate for &#946;-oxidation, can elevate the mitochondrial mass and glucose transporter protein type 1 (GLUT1) expression as well as stimulate OXPHOS and glutaminolysis instead of glycolysis in activated CD8+ T cells. Not only that, butyrate can promote cell metabolism and enhance the memory potential of activated CD8+ T cells. In this process, butyrate decoups the tricarboxylic acid cycle from glycolytic input to CD8+ T cells, which prefertionally provides fuel for oxidative phosphorylation through ongoing glutamine utilization and fatty acid catabolism (<xref rid="B83" ref-type="bibr">83</xref>). SCFAs, as the substrate for &#946;-oxidation, can elevate the mitochondrial mass and glucose transporter protein type 1 (GLUT1) expression as well as stimulate OXPHOS and glutaminolysis instead of glycolysis in activated CD8+ T cells (<xref rid="B108" ref-type="bibr">108</xref>). The gut microbiota-derived metabolite butyrate modulates the effector function of CD8+ T cells (<xref rid="B83" ref-type="bibr">83</xref>). Additionally, pentanoate, a subdominant type of SCFA, was found to directly affect CD4+ T cell metabolism. Pentanoate stimulated glycolysis and increased acetyl-CoA levels in Th17 cells (<xref rid="B109" ref-type="bibr">109</xref>). Isoallolithocholic acid (isoalloLCA), a secondary bile acid, augments OXPHOS in CD4+ T cells, which is indicated by the elevated oxygen consumption and mitochondrial membrane potential (<xref rid="B104" ref-type="bibr">104</xref>). As a key metabolite produced by glycolytic metabolism of glucose molecules, lactic acid prevents the upregulation of activated T nuclear factors in T cells and NK cells, thus resulting in reduced IFN-&#947; production. As a potent inhibitor of T and NK cell function and survival, lactic acid can cause tumor immune escape (<xref rid="B110" ref-type="bibr">110</xref>). Besides, lactate can increase the dryness of CD8+T cells and enhance anti-tumor immunity (<xref rid="B111" ref-type="bibr">111</xref>). In addition, studies have shown that lactic acid is an active checkpoint for Treg cell function, and it can up-regulate PD-1 expression in highly glycolytic TME (<xref rid="B112" ref-type="bibr">112</xref>). Treg cells up-regulate pathways involved in the metabolism of lactic acid. Lactate uptake is essential for the function of peripheral treg cells, but it requires intratumoral uptake, thereby resulting in slower tumor growth and increased response to immunotherapy (<xref rid="B50" ref-type="bibr">50</xref>).</p></sec></sec><sec id="s5"><title>T-cell energy metabolism in cancer immunotherapy</title><p>T cells are central players in mounting an effective anti-tumor&#160;immune response. Activated T cells must adjust their metabolism to meet the energy requirements associated with rapid proliferation and effector function. Therefore, targeting T cell metabolism is a promising strategy in the development of T&#160;cell-based immunotherapeutics. Current T cell-based immunotherapeutics mainly include ICIs and autologous T&#160;cell therapies.</p></sec><sec id="s6"><title>ICIs</title><p>Immune checkpoints are crucial elements of the immune system that contribute to the maintenance of immune homeostasis by controlling the type, intensity, and duration of immune responses. Immune checkpoints are ligand&#8211;receptor complexes that modulate immune responses by transmitting costimulatory or inhibitory signals. The overexpression of immune checkpoints in cancer are linked to T cell exhaustion, thus leading to dysfunctional T lymphocytes that exhibit decreased effector function and impaired proliferation (<xref rid="B113" ref-type="bibr">113</xref>). Among the numerous tumor-associated immune checkpoints, CTLA-4 and PD-1 are two critical molecules, and targeting them has demonstrated effectiveness in promoting the activation of anti-tumor immune responses (<xref rid="B114" ref-type="bibr">114</xref>). ICIs are monoclonal antibodies (mAbs) that block immune checkpoint proteins expressed on immune cells, such as T cells and tumor cells, thereby releasing the brakes on the immune system and enabling the elimination of tumor cells (<xref rid="B115" ref-type="bibr">115</xref>). mAbs that specifically target co-inhibitory immune checkpoints, such as PD-1 and CTLA-4, have demonstrated clinical effectiveness in various types of cancers, including CRC (<xref rid="B116" ref-type="bibr">116</xref>, <xref rid="B117" ref-type="bibr">117</xref>). However, ICIs have not shown any clinical benefit or improvement in survival in patients with non-mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), accounting for 96% of the patients with metastatic disease (<xref rid="B118" ref-type="bibr">118</xref>, <xref rid="B119" ref-type="bibr">119</xref>).</p><p>Additionally, immunosuppressive receptors alter the anti-tumor effects of T cells by interfering with their metabolism. It has been reported that PD-1 can affect the metabolic reprogramming of T cells by suppressing glycolysis and elevating lipolysis and FAO (<xref rid="B120" ref-type="bibr">120</xref>), which suggested that immune checkpoint blockade can promote the metabolic reprogramming of Teff cells, thus enhancing their anti-tumor effect. Conversely, CTLA-4 inhibits glycolysis without augmenting FAO, which suggestes that CTLA-4 sustains the metabolic profile of non-activated cells. Collectively, PD1- and CTLA4-targted ICIs enhance effector T cell function via increasing glucose influx and glycolysis. Importantly, the extrinsic metabolic barriers on tumor-infiltrating immune cells caused by the TME, such as lactate accumulation, hypoxia, and mitochondrial dysfunction, can be overcome by ICIs (<xref rid="B121" ref-type="bibr">121</xref>). The anti-PD1 blockade and bezafibrate combination treatment has been shown to promote mitochondrial biogenesis, FAO, and OXPHOS in CD8+ T cells (<xref rid="B122" ref-type="bibr">122</xref>). Therefore, targeting T cell metabolism represents a promising approach for the improvement of the outcomes of ICIs.</p></sec><sec id="s7"><title>Autologous T cell therapies</title><p>Autologous T cell therapies mainly employ CAR- and T cell receptor (TCR)- based therapies that recognize antigens on targeted tumor cells and offer treatment options for cancer (<xref rid="B123" ref-type="bibr">123</xref>, <xref rid="B124" ref-type="bibr">124</xref>). CAR-T cells are engineered T cells that express synthetic T cell receptors and enable them to recognize and target tumor surface antigens. These engineered T cells redirect the polyclonal T cell response toward tumor cells, thus resulting in the eradication of tumors (<xref rid="B125" ref-type="bibr">125</xref>). Several CAR-T cell therapies have been used to treat hematological malignancies (<xref rid="B126" ref-type="bibr">126</xref>). However, some obstacles, such as the absence of suitable target antigens and an immunosuppressive TME, hinder their clinical application (<xref rid="B127" ref-type="bibr">127</xref>). TCR-T cells can recognize antigens expressed on both the cell surface and within intracellular compartments, thus making it a compelling avenue for solid tumor treatment (<xref rid="B128" ref-type="bibr">128</xref>). Interestingly, the metabolic reprogramming of T cells through gene editing can help T cells resist unfavorable environmental factors in TME. The mitochondrial regulator PPARGC1A(peroxisome proliferator activating receptor &#947;, coactivator 1&#945;) is often described as a major regulator of mitochondrial biogenesis and a central player in regulating antioxidant defense, capable of reducing aging in vascular smooth muscle cells (VSMCs) (<xref rid="B129" ref-type="bibr">129</xref>). However, there is growing evidence that PGC-1&#945; is also involved in complex regulation of mitochondrial mass beyond biogenesis, including mitochondrial network dynamics and autophagy clearance of damaged mitochondria. Furthermore, it was found that the deficiency of PGC-1&#945; can cause the loss of mitochondrial function of Teff cells, and increasing the expression of PGC-1&#945; can save the mitochondrial function of Teff cells and increase the production of cytokines, thus enhancing the anti-tumor effect of T cells (<xref rid="B130" ref-type="bibr">130</xref>). Moreover, lysine demethylase 3A (KDM3A) can bind to PGC-1&#945; and demethylate the monomethyl lysine (K) 224 of PGC-1&#945; under normal oxygen conditions. Up-regulated expression of PGC-1&#945;K224R mutant can promote mitochondrial biogenesis, reactive oxygen species (ROS) production and tumor cell apoptosis in mice under hypoxia, and inhibit the growth of brain tumors (<xref rid="B131" ref-type="bibr">131</xref>). Furthermore, the study found that cholesterol esterification enzyme ACAT1 is also a good regulatory target in the metabolic pathway of T cells. Knockout or inhibition of acetyl-coacetyltransferase (ACAT1) can increase the cholesterol concentration of CD8+ T cell membrane, so that this type of killer T cells can be more easily polymerized than the original and better form immune synapses, thereby improving antigen sensitivity and improving immune efficacy (<xref rid="B81" ref-type="bibr">81</xref>). Moreover, studies have confirmed that the combination of ACAT inhibitor Avasimibe and PD-1 antibody can further improve the effectiveness of tumor immunotherapy. In addition, Fan J, et&#160;al. discovered that ACAT1 mainly sends signals through PDP1 and PDHA to promote Warburg effect and tumor growth. When ACAT1 is knocked down, tumor growth is inhibited. These results also suggest the potential of ACAT1 as a target for anti-cancer drugs (<xref rid="B82" ref-type="bibr">82</xref>). In conclusion, metabolic remodeling of T cells through gene editing or transduction of specific genes <italic toggle="yes">in vitro</italic> can enhance the antitumor properties of T cells. The development of new strategies in improving the metabolic fitness of autologous T cells can improve the therapeutic efficacy of anti-tumor immunity.</p><p>Furthermore, TGF-beta has gradually been found to play an important role in T cell energy metabolism and cancer immune evasion. Checkpoint blocking drugs represented by PD-1/PD-L1 antibodies have achieved good results in the treatment of a variety of cancers. However, the overall efficiency is still not high. Among them, the heterogeneity of tumor and the diversity of immune microenvironment are the main reasons limiting the therapeutic effect. Recent studies have revealed that anti-TGF-&#946;/PD-L1 bispecific antibody YM101 can simultaneously block the PD-1/PD-L1 and TGFR2/TGF-&#946; signaling pathways, promote the activation of efficient T cells, regulate the tumor microenvironment, and reverse immunosuppression and fibrosis (<xref rid="B132" ref-type="bibr">132</xref>). Meanwhile, its anti-tumor effect superior to PD-L1 monoclonal antibody has been verified in a variety of mouse tumor bearing models. In addition, Yi M et&#160;al. also constructed a bispecific antibody (called BiTP) against TGF-&#946; and human PD-L1 and found that BiTP retained the binding affinity and biological activity of the parent antibody, and it had strong anti-tumor activity against the parent antibody in triple-negative breast cancer (TNBC) (<xref rid="B133" ref-type="bibr">133</xref>). These studies indicate that new drugs based on TGF-&#946;/PD-L1 double antibodies are expected to provide a new solution to the existing immunotherapy dilemma, and have important clinical significance and translational value.</p></sec><sec sec-type="conclusions" id="s8"><title>Conclusion</title><p>Metabolic reprogramming is the metabolic change that cells undergo in response to various stressors. Similar to tumor cells, activated T cells in the TME undergo metabolic reprogramming to acquire energy, and the failure of activated T cells to obtain sufficient nutrients or undergo metabolic re-wiring can damage their effector function. Factors, such as hypoxia, lactate accumulation, and the gut microbiome, may affect T cell activation and energy metabolism. Targeting T cell metabolism is a potentially promising approach for eliciting durable immune responses in tumors that are resistant to conventional immunotherapies. Therefore, therapeutic approaches targeting T-cell metabolism may offer an opportunity to optimize and improve current anti-tumor therapeutic strategies.</p></sec><sec sec-type="author-contributions" id="s9"><title>Author contributions</title><p>LX: Writing &#8211; original draft. SY: Writing &#8211; original draft. CJ: Writing &#8211; original draft, Validation. SYF: Validation, Writing &#8211; original draft. WX: Writing &#8211; original draft, Visualization. ZW: Writing &#8211; original draft. HS: Writing &#8211; original draft. YX: Writing &#8211; original draft.</p></sec></body><back><sec sec-type="COI-statement" id="s11"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SW</given-names></name><name name-style="western"><surname>Cho</surname><given-names>BC</given-names></name><name name-style="western"><surname>Kang</surname><given-names>JH</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DW</given-names></name><etal/></person-group>. <article-title>Real-world experience of nivolumab in non-small cell lung cancer in korea</article-title>. <source>Cancer Res Treat</source> (<year>2020</year>) <volume>52</volume>(<issue>4</issue>):<page-range>1112&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4143/crt.2020.245</pub-id><pub-id pub-id-type="pmcid">PMC7577826</pub-id><pub-id pub-id-type="pmid">32599984</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beyar Katz</surname><given-names>O</given-names></name><name name-style="western"><surname>Perry</surname><given-names>C</given-names></name><name name-style="western"><surname>Grisariu-Greenzaid</surname><given-names>S</given-names></name><name name-style="western"><surname>Yehudai-Ofir</surname><given-names>D</given-names></name><name name-style="western"><surname>Luttwak</surname><given-names>E</given-names></name><name name-style="western"><surname>Avni</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study</article-title>. <source>Eur J Haematol</source> (<year>2023</year>) <volume>111</volume>(<issue>1</issue>):<fpage>63</fpage>&#8211;<lpage>71</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/ejh.13968</pub-id><pub-id pub-id-type="pmid">36964939</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mai</surname><given-names>D</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>O</given-names></name><name name-style="western"><surname>Reff</surname><given-names>J</given-names></name><name name-style="western"><surname>Fan</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Scholler</surname><given-names>J</given-names></name><name name-style="western"><surname>Sheppard</surname><given-names>NC</given-names></name><etal/></person-group>. <article-title>Combined disruption of T cell inflammatory regulators regnase-1 and roquin-1 enhances antitumor activity of engineered human T cells</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2023</year>) <volume>120</volume>(<issue>12</issue>):<elocation-id>e2218632120</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.2218632120</pub-id><pub-id pub-id-type="pmid">36920923</pub-id><pub-id pub-id-type="pmcid">PMC10041166</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reschke</surname><given-names>R</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Flood</surname><given-names>B</given-names></name><name name-style="western"><surname>Higgs</surname><given-names>EF</given-names></name><name name-style="western"><surname>Hatogai</surname><given-names>K</given-names></name><name name-style="western"><surname>Gajewski</surname><given-names>TF</given-names></name></person-group>. <article-title>Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma</article-title>. <source>J Immunother Cancer</source> (<year>2021</year>) <volume>9</volume>(<issue>9</issue>):<elocation-id>e003521</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1136/jitc-2021-003521</pub-id><pub-id pub-id-type="pmid">34593622</pub-id><pub-id pub-id-type="pmcid">PMC8487215</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonarakis</surname><given-names>ES</given-names></name><name name-style="western"><surname>Piulats</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gross-Goupil</surname><given-names>M</given-names></name><name name-style="western"><surname>Goh</surname><given-names>J</given-names></name><name name-style="western"><surname>Ojamaa</surname><given-names>K</given-names></name><name name-style="western"><surname>Hoimes</surname><given-names>CJ</given-names></name><etal/></person-group>. <article-title>Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study</article-title>. <source>J Clin Oncol</source> (<year>2020</year>) <volume>38</volume>(<issue>5</issue>):<fpage>395</fpage>&#8211;<lpage>405</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.19.01638</pub-id><pub-id pub-id-type="pmid">31774688</pub-id><pub-id pub-id-type="pmcid">PMC7186583</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roth</surname><given-names>MT</given-names></name><name name-style="western"><surname>Das</surname><given-names>S</given-names></name></person-group>. <article-title>Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy</article-title>. <source>Expert Rev Anticancer Ther</source> (<year>2021</year>) <volume>21</volume>(<issue>2</issue>):<page-range>229&#8211;38</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/14737140.2021.1851201</pub-id><pub-id pub-id-type="pmcid">PMC8118165</pub-id><pub-id pub-id-type="pmid">33183114</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Chimeric oncolytic adenovirus armed chemokine rantes for treatment of breast cancer</article-title>. <source>Bioeng (Basel)</source> (<year>2022</year>) <volume>9</volume>(<issue>8</issue>):<elocation-id>342</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/bioengineering9080342</pub-id><pub-id pub-id-type="pmcid">PMC9332706</pub-id><pub-id pub-id-type="pmid">35892755</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heintzman</surname><given-names>DR</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>EL</given-names></name><name name-style="western"><surname>Rathmell</surname><given-names>JC</given-names></name></person-group>. <article-title>Microenvironmental in fluences on T cell immunity in cancer and in flammation</article-title>. <source>Cell Mol Immunol</source> (<year>2022</year>) <volume>19</volume>(<issue>3</issue>):<page-range>316&#8211;26</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41423-021-00833-2</pub-id><pub-id pub-id-type="pmcid">PMC8762638</pub-id><pub-id pub-id-type="pmid">35039633</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name></person-group>. <article-title>T cells in health and disease</article-title>. <source>Signal Transduct Target Ther</source> (<year>2023</year>) <volume>8</volume>(<issue>1</issue>):<fpage>235</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41392-023-01471-y</pub-id><pub-id pub-id-type="pmid">37332039</pub-id><pub-id pub-id-type="pmcid">PMC10277291</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Liang</surname><given-names>T</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Regulatory T cell plasticity and stability and autoimmune diseases</article-title>. <source>Clin Rev Allergy Immunol</source> (<year>2020</year>) <volume>58</volume>(<issue>1</issue>):<fpage>52</fpage>&#8211;<lpage>70</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s12016-018-8721-0</pub-id><pub-id pub-id-type="pmid">30449014</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banta</surname><given-names>KL</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Chitre</surname><given-names>AS</given-names></name><name name-style="western"><surname>Au-Yeung</surname><given-names>A</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>C</given-names></name><name name-style="western"><surname>O'Gorman</surname><given-names>WE</given-names></name><etal/></person-group>. <article-title>Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses</article-title>. <source>Immunity</source> (<year>2022</year>) <volume>55</volume>(<issue>3</issue>):<fpage>512</fpage>&#8211;<lpage>526.e9</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2022.02.005</pub-id><pub-id pub-id-type="pmid">35263569</pub-id><pub-id pub-id-type="pmcid">PMC9287124</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masuda</surname><given-names>K</given-names></name><name name-style="western"><surname>Kornberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><name name-style="western"><surname>Suek</surname><given-names>N</given-names></name><name name-style="western"><surname>Botella</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Multiplexed single-cell analysis reveals prognostic and nonprognostic T cell types in human colorectal cancer</article-title>. <source>JCI Insight</source> (<year>2022</year>) <volume>7</volume>(<issue>7</issue>):<elocation-id>e154646</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1172/jci.insight.154646</pub-id><pub-id pub-id-type="pmid">35192548</pub-id><pub-id pub-id-type="pmcid">PMC9057629</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hua</surname><given-names>H</given-names></name><name name-style="western"><surname>Gong</surname><given-names>M</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Immune-infiltrating signature-based classification reveals CD103(+) CD39(+) T cells associate with colorectal cancer prognosis and response to immunotherapy</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>1011590</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1011590</pub-id><pub-id pub-id-type="pmid">36311750</pub-id><pub-id pub-id-type="pmcid">PMC9596778</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>JD</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J</given-names></name><name name-style="western"><surname>Slaney</surname><given-names>CY</given-names></name><name name-style="western"><surname>Kallies</surname><given-names>A</given-names></name><name name-style="western"><surname>Beavis</surname><given-names>PA</given-names></name><name name-style="western"><surname>Darcy</surname><given-names>PK</given-names></name></person-group>. <article-title>Cellular networks controlling T cell persistence in adoptive cell therapy</article-title>. <source>Nat Rev Immunol</source> (<year>2021</year>) <volume>21</volume>(<issue>12</issue>):<page-range>769&#8211;84</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41577-021-00539-6</pub-id><pub-id pub-id-type="pmid">33879873</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response</article-title>. <source>Cell Res</source> (<year>2022</year>) <volume>32</volume>(<issue>6</issue>):<page-range>530&#8211;42</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41422-022-00627-9</pub-id><pub-id pub-id-type="pmcid">PMC9160085</pub-id><pub-id pub-id-type="pmid">35165422</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirschhorn</surname><given-names>D</given-names></name><name name-style="western"><surname>Budhu</surname><given-names>S</given-names></name><name name-style="western"><surname>Kraehenbuehl</surname><given-names>L</given-names></name><name name-style="western"><surname>Gigoux</surname><given-names>M</given-names></name><name name-style="western"><surname>Schr&#246;der</surname><given-names>D</given-names></name><name name-style="western"><surname>Chow</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants</article-title>. <source>Cell</source> (<year>2023</year>) <volume>186</volume>(<issue>7</issue>):<fpage>1432</fpage>&#8211;<lpage>1447.e17</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2023.03.007</pub-id><pub-id pub-id-type="pmid">37001503</pub-id><pub-id pub-id-type="pmcid">PMC10994488</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Jia</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Liang</surname><given-names>M</given-names></name><name name-style="western"><surname>Guo</surname><given-names>T</given-names></name><name name-style="western"><surname>Du</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance</article-title>. <source>Signal Transduct Target Ther</source> (<year>2023</year>) <volume>8</volume>(<issue>1</issue>):<fpage>246</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41392-023-01450-3</pub-id><pub-id pub-id-type="pmid">37357254</pub-id><pub-id pub-id-type="pmcid">PMC10290989</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>S</given-names></name><name name-style="western"><surname>Aznar</surname><given-names>MA</given-names></name><name name-style="western"><surname>Rech</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Good</surname><given-names>CR</given-names></name><name name-style="western"><surname>Kuramitsu</surname><given-names>S</given-names></name><name name-style="western"><surname>Da</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells</article-title>. <source>Immunity</source> (<year>2023</year>) <volume>56</volume>(<issue>10</issue>):<fpage>2388</fpage>&#8211;<lpage>2407.e9</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2023.09.001</pub-id><pub-id pub-id-type="pmid">37776850</pub-id><pub-id pub-id-type="pmcid">PMC10591801</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Virassamy</surname><given-names>B</given-names></name><name name-style="western"><surname>Caramia</surname><given-names>F</given-names></name><name name-style="western"><surname>Savas</surname><given-names>P</given-names></name><name name-style="western"><surname>Sant</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Christo</surname><given-names>SN</given-names></name><etal/></person-group>. <article-title>Intratumoral CD8(+) T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer</article-title>. <source>Cancer Cell</source> (<year>2023</year>) <volume>41</volume>(<issue>3</issue>):<fpage>585</fpage>&#8211;<lpage>601.e8</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ccell.2023.01.004</pub-id><pub-id pub-id-type="pmid">36827978</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrejeva</surname><given-names>G</given-names></name><name name-style="western"><surname>Rathmell</surname><given-names>JC</given-names></name></person-group>. <article-title>Similarities and distinctions of cancer and immune metabolism in inflammation and tumors</article-title>. <source>Cell Metab</source> (<year>2017</year>) <volume>26</volume>(<issue>1</issue>):<fpage>49</fpage>&#8211;<lpage>70</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cmet.2017.06.004</pub-id><pub-id pub-id-type="pmid">28683294</pub-id><pub-id pub-id-type="pmcid">PMC5555084</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menk</surname><given-names>AV</given-names></name><name name-style="western"><surname>Scharping</surname><given-names>NE</given-names></name><name name-style="western"><surname>Moreci</surname><given-names>RS</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X</given-names></name><name name-style="western"><surname>Guy</surname><given-names>C</given-names></name><name name-style="western"><surname>Salvatore</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Early TCR signaling induces rapid aerobic glycolysis enabling distinct acute T cell effector functions</article-title>. <source>Cell Rep</source> (<year>2018</year>) <volume>22</volume>(<issue>6</issue>):<page-range>1509&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.celrep.2018.01.040</pub-id><pub-id pub-id-type="pmcid">PMC5973810</pub-id><pub-id pub-id-type="pmid">29425506</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bantug</surname><given-names>GR</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G</given-names></name><name name-style="western"><surname>Hess</surname><given-names>C</given-names></name></person-group>. <article-title>The spectrum of T cell metabolism in health and disease</article-title>. <source>Nat Rev Immunol</source> (<year>2018</year>) <volume>18</volume>(<issue>1</issue>):<fpage>19</fpage>&#8211;<lpage>34</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nri.2017.99</pub-id><pub-id pub-id-type="pmid">28944771</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>CH</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>JD</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>LB</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Faubert</surname><given-names>B</given-names></name><name name-style="western"><surname>Villarino</surname><given-names>AV</given-names></name><name name-style="western"><surname>O'Sullivan</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Posttranscriptional control of T cell effector function by aerobic glycolysis</article-title>. <source>Cell</source> (<year>2013</year>) <volume>153</volume>(<issue>6</issue>):<page-range>1239&#8211;51</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2013.05.016</pub-id><pub-id pub-id-type="pmcid">PMC3804311</pub-id><pub-id pub-id-type="pmid">23746840</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Renner</surname><given-names>K</given-names></name><name name-style="western"><surname>Bruss</surname><given-names>C</given-names></name><name name-style="western"><surname>Schnell</surname><given-names>A</given-names></name><name name-style="western"><surname>Koehl</surname><given-names>G</given-names></name><name name-style="western"><surname>Becker</surname><given-names>HM</given-names></name><name name-style="western"><surname>Fante</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy</article-title>. <source>Cell Rep</source> (<year>2019</year>) <volume>29</volume>(<issue>1</issue>):<fpage>135</fpage>&#8211;<lpage>150.e9</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.celrep.2019.08.068</pub-id><pub-id pub-id-type="pmid">31577944</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>KG</given-names></name><name name-style="western"><surname>Stromnes</surname><given-names>IM</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>PD</given-names></name></person-group>. <article-title>Obstacles posed by the tumor microenvironment to T cell activity: A case for synergistic therapies</article-title>. <source>Cancer Cell</source> (<year>2017</year>) <volume>31</volume>(<issue>3</issue>):<page-range>311&#8211;25</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ccell.2017.02.008</pub-id><pub-id pub-id-type="pmcid">PMC5423788</pub-id><pub-id pub-id-type="pmid">28292435</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scharping</surname><given-names>NE</given-names></name><name name-style="western"><surname>Rivadeneira</surname><given-names>DB</given-names></name><name name-style="western"><surname>Menk</surname><given-names>AV</given-names></name><name name-style="western"><surname>Vignali</surname><given-names>PDA</given-names></name><name name-style="western"><surname>Ford</surname><given-names>BR</given-names></name><name name-style="western"><surname>Rittenhouse</surname><given-names>NL</given-names></name><etal/></person-group>. <article-title>Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion</article-title>. <source>Nat Immunol</source> (<year>2021</year>) <volume>22</volume>(<issue>2</issue>):<page-range>205&#8211;15</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41590-020-00834-9</pub-id><pub-id pub-id-type="pmcid">PMC7971090</pub-id><pub-id pub-id-type="pmid">33398183</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ron-Harel</surname><given-names>N</given-names></name><name name-style="western"><surname>Santos</surname><given-names>D</given-names></name><name name-style="western"><surname>Ghergurovich</surname><given-names>JM</given-names></name><name name-style="western"><surname>Sage</surname><given-names>PT</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>A</given-names></name><name name-style="western"><surname>Lovitch</surname><given-names>SB</given-names></name><etal/></person-group>. <article-title>Mitochondrial biogenesis and proteome remodeling promote one-carbon metabolism for T cell activation</article-title>. <source>Cell Metab</source> (<year>2016</year>) <volume>24</volume>(<issue>1</issue>):<page-range>104&#8211;17</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cmet.2016.06.007</pub-id><pub-id pub-id-type="pmcid">PMC5330619</pub-id><pub-id pub-id-type="pmid">27411012</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>PB</given-names></name><etal/></person-group>. <article-title>Immunometabolism: A new target for improving cancer immunotherapy</article-title>. <source>Adv Cancer Res</source> (<year>2019</year>) <volume>143</volume>:<fpage>195</fpage>&#8211;<lpage>253</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/bs.acr.2019.03.004</pub-id><pub-id pub-id-type="pmid">31202359</pub-id><pub-id pub-id-type="pmcid">PMC6822174</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reina-Campos</surname><given-names>M</given-names></name><name name-style="western"><surname>Scharping</surname><given-names>NE</given-names></name><name name-style="western"><surname>Goldrath</surname><given-names>AW</given-names></name></person-group>. <article-title>CD8(+) T cell metabolism in infection and cancer</article-title>. <source>Nat Rev Immunol</source> (<year>2021</year>) <volume>21</volume>(<issue>11</issue>):<page-range>718&#8211;38</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41577-021-00537-8</pub-id><pub-id pub-id-type="pmcid">PMC8806153</pub-id><pub-id pub-id-type="pmid">33981085</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimeloe</surname><given-names>S</given-names></name><name name-style="western"><surname>Burgener</surname><given-names>AV</given-names></name><name name-style="western"><surname>Gr&#228;hlert</surname><given-names>J</given-names></name><name name-style="western"><surname>Hess</surname><given-names>C</given-names></name></person-group>. <article-title>T-cell metabolism governing activation, proliferation and differentiation; a modular view</article-title>. <source>Immunology</source> (<year>2017</year>) <volume>150</volume>(<issue>1</issue>):<fpage>35</fpage>&#8211;<lpage>44</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/imm.12655</pub-id><pub-id pub-id-type="pmid">27479920</pub-id><pub-id pub-id-type="pmcid">PMC5341500</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leone</surname><given-names>RD</given-names></name><name name-style="western"><surname>Powell</surname><given-names>JD</given-names></name></person-group>. <article-title>Metabolism of immune cells in cancer</article-title>. <source>Nat Rev Cancer</source> (<year>2020</year>) <volume>20</volume>(<issue>9</issue>):<page-range>516&#8211;31</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41568-020-0273-y</pub-id><pub-id pub-id-type="pmcid">PMC8041116</pub-id><pub-id pub-id-type="pmid">32632251</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kouidhi</surname><given-names>S</given-names></name><name name-style="western"><surname>Elgaaied</surname><given-names>AB</given-names></name><name name-style="western"><surname>Chouaib</surname><given-names>S</given-names></name></person-group>. <article-title>Impact of metabolism on T-cell differentiation and function and cross talk with tumor microenvironment</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<elocation-id>270</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2017.00270</pub-id><pub-id pub-id-type="pmid">28348562</pub-id><pub-id pub-id-type="pmcid">PMC5346542</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B</given-names></name></person-group>. <article-title>Metabolic plasticity and regulation of T cell exhaustion</article-title>. <source>Immunology</source> (<year>2022</year>) <volume>167</volume>(<issue>4</issue>):<page-range>482&#8211;94</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/imm.13575</pub-id><pub-id pub-id-type="pmid">36088582</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porporato</surname><given-names>PE</given-names></name><name name-style="western"><surname>Filigheddu</surname><given-names>N</given-names></name><name name-style="western"><surname>Pedro</surname><given-names>JMB</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L</given-names></name></person-group>. <article-title>Mitochondrial metabolism and cancer</article-title>. <source>Cell Res</source> (<year>2018</year>) <volume>28</volume>(<issue>3</issue>):<page-range>265&#8211;80</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/cr.2017.155</pub-id><pub-id pub-id-type="pmcid">PMC5835768</pub-id><pub-id pub-id-type="pmid">29219147</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>CL</given-names></name><name name-style="western"><surname>Ponneri Babuharisankar</surname><given-names>A</given-names></name><name name-style="western"><surname>Lin</surname><given-names>YC</given-names></name><name name-style="western"><surname>Lien</surname><given-names>HW</given-names></name><name name-style="western"><surname>Lo</surname><given-names>YK</given-names></name><name name-style="western"><surname>Chou</surname><given-names>HY</given-names></name><etal/></person-group>. <article-title>Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend</article-title>? <source>J BioMed Sci</source> (<year>2022</year>) <volume>29</volume>(<issue>1</issue>):<fpage>74</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12929-022-00859-2</pub-id><pub-id pub-id-type="pmid">36154922</pub-id><pub-id pub-id-type="pmcid">PMC9511749</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zielonka</surname><given-names>J</given-names></name><name name-style="western"><surname>Kalyanaraman</surname><given-names>B</given-names></name></person-group>. <article-title>"ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis"-a critical commentary</article-title>. <source>Free Radic Biol Med</source> (<year>2008</year>) <volume>45</volume>(<issue>9</issue>):<page-range>1217&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2008.07.025</pub-id><pub-id pub-id-type="pmcid">PMC3595710</pub-id><pub-id pub-id-type="pmid">18789385</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>YR</given-names></name><name name-style="western"><surname>Imrichova</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Chao</surname><given-names>T</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gao</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Disturbed mitochondrial dynamics in CD8(+) TILs reinforce T cell exhaustion</article-title>. <source>Nat Immunol</source> (<year>2020</year>) <volume>21</volume>(<issue>12</issue>):<page-range>1540&#8211;51</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41590-020-0793-3</pub-id><pub-id pub-id-type="pmid">33020660</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogando</surname><given-names>J</given-names></name><name name-style="western"><surname>S&#225;ez</surname><given-names>ME</given-names></name><name name-style="western"><surname>Santos</surname><given-names>J</given-names></name><name name-style="western"><surname>Nuevo-Tapioles</surname><given-names>C</given-names></name><name name-style="western"><surname>Gut</surname><given-names>M</given-names></name><name name-style="western"><surname>Esteve-Codina</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8(+) t lymphocytes</article-title>. <source>J Immunother Cancer</source> (<year>2019</year>) <volume>7</volume>(<issue>1</issue>):<fpage>151</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s40425-019-0628-7</pub-id><pub-id pub-id-type="pmid">31196176</pub-id><pub-id pub-id-type="pmcid">PMC6567413</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buck</surname><given-names>MD</given-names></name><name name-style="western"><surname>O'Sullivan</surname><given-names>D</given-names></name><name name-style="western"><surname>Klein Geltink</surname><given-names>RI</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>JD</given-names></name><name name-style="western"><surname>Chang</surname><given-names>CH</given-names></name><name name-style="western"><surname>Sanin</surname><given-names>DE</given-names></name><etal/></person-group>. <article-title>Mitochondrial dynamics controls T cell fate through metabolic programming</article-title>. <source>Cell</source> (<year>2016</year>) <volume>166</volume>(<issue>1</issue>):<fpage>63</fpage>&#8211;<lpage>76</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2016.05.035</pub-id><pub-id pub-id-type="pmid">27293185</pub-id><pub-id pub-id-type="pmcid">PMC4974356</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sedlackova</surname><given-names>L</given-names></name><name name-style="western"><surname>Korolchuk</surname><given-names>VI</given-names></name></person-group>. <article-title>Mitochondrial quality control as a key determinant of cell survival</article-title>. <source>Biochim Biophys Acta Mol Cell Res</source> (<year>2019</year>) <volume>1866</volume>(<issue>4</issue>):<page-range>575&#8211;87</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.bbamcr.2018.12.012</pub-id><pub-id pub-id-type="pmid">30594496</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Renner</surname><given-names>K</given-names></name><name name-style="western"><surname>Singer</surname><given-names>K</given-names></name><name name-style="western"><surname>Koehl</surname><given-names>GE</given-names></name><name name-style="western"><surname>Geissler</surname><given-names>EK</given-names></name><name name-style="western"><surname>Peter</surname><given-names>K</given-names></name><name name-style="western"><surname>Siska</surname><given-names>PJ</given-names></name><etal/></person-group>. <article-title>Metabolic hallmarks of tumor and immune cells in the tumor microenvironment</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<elocation-id>248</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2017.00248</pub-id><pub-id pub-id-type="pmid">28337200</pub-id><pub-id pub-id-type="pmcid">PMC5340776</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>CH</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J</given-names></name><name name-style="western"><surname>O'Sullivan</surname><given-names>D</given-names></name><name name-style="western"><surname>Buck</surname><given-names>MD</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>Metabolic competition in the tumor microenvironment is a driver of cancer progression</article-title>. <source>Cell</source> (<year>2015</year>) <volume>162</volume>(<issue>6</issue>):<page-range>1229&#8211;41</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2015.08.016</pub-id><pub-id pub-id-type="pmcid">PMC4864363</pub-id><pub-id pub-id-type="pmid">26321679</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stirling</surname><given-names>ER</given-names></name><name name-style="western"><surname>Terabe</surname><given-names>M</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>AS</given-names></name><name name-style="western"><surname>Kooshki</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamaleyeva</surname><given-names>LM</given-names></name><name name-style="western"><surname>Alexander-Miller</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response</article-title>. <source>J Immunother Cancer</source> (<year>2022</year>) <volume>10</volume>(<issue>11</issue>):<elocation-id>e004712</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1136/jitc-2022-004712</pub-id><pub-id pub-id-type="pmid">36418073</pub-id><pub-id pub-id-type="pmcid">PMC9685258</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palazon</surname><given-names>A</given-names></name><name name-style="western"><surname>Tyrakis</surname><given-names>PA</given-names></name><name name-style="western"><surname>Macias</surname><given-names>D</given-names></name><name name-style="western"><surname>Veli&#231;a</surname><given-names>P</given-names></name><name name-style="western"><surname>Rundqvist</surname><given-names>H</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>An HIF-1a/VEGF-A axis in cytotoxic T cells regulates tumor progression</article-title>. <source>Cancer Cell</source> (<year>2017</year>) <volume>32</volume>(<issue>5</issue>):<fpage>669</fpage>&#8211;<lpage>683.e5</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ccell.2017.10.003</pub-id><pub-id pub-id-type="pmid">29136509</pub-id><pub-id pub-id-type="pmcid">PMC5691891</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Hochrein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Eckstein</surname><given-names>M</given-names></name><name name-style="western"><surname>Gubert</surname><given-names>GF</given-names></name><name name-style="western"><surname>Kn&#246;pper</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1a-mediated glycolytic reprogramming</article-title>. <source>NatCommun</source> (<year>2023</year>) <volume>14</volume>(<issue>1</issue>):<fpage>6858</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-023-42634-3</pub-id><pub-id pub-id-type="pmcid">PMC10611730</pub-id><pub-id pub-id-type="pmid">37891230</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Copeland</surname><given-names>CA</given-names></name><name name-style="western"><surname>Olenchock</surname><given-names>BA</given-names></name><name name-style="western"><surname>Ziehr</surname><given-names>D</given-names></name><name name-style="western"><surname>McGarrity</surname><given-names>S</given-names></name><name name-style="western"><surname>Leahy</surname><given-names>K</given-names></name><name name-style="western"><surname>Young</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>MYC overrides HIF-1a to regulate proliferating primary cell metabolism in hypoxia</article-title>. <source>Elife</source> (<year>2023</year>) <volume>12</volume>:<fpage>e82597</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.7554/eLife.82597</pub-id><pub-id pub-id-type="pmid">37428010</pub-id><pub-id pub-id-type="pmcid">PMC10332812</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>SH</given-names></name><name name-style="western"><surname>Raybuck</surname><given-names>AL</given-names></name><name name-style="western"><surname>Blagih</surname><given-names>J</given-names></name><name name-style="western"><surname>Kemboi</surname><given-names>E</given-names></name><name name-style="western"><surname>Haase</surname><given-names>VH</given-names></name><name name-style="western"><surname>Jones</surname><given-names>RG</given-names></name><etal/></person-group>. <article-title>Hypoxia-inducible factors in CD4(+) T cells promote metabolism,switch cytokine secretion, and T cell help in humoral immunity</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2019</year>) <volume>116</volume>(<issue>18</issue>):<page-range>8975&#8211;84</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.1811702116</pub-id><pub-id pub-id-type="pmcid">PMC6500120</pub-id><pub-id pub-id-type="pmid">30988188</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macintyre</surname><given-names>AN</given-names></name><name name-style="western"><surname>Gerriets</surname><given-names>VA</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>AG</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>RD</given-names></name><name name-style="western"><surname>Rudolph</surname><given-names>MC</given-names></name><etal/></person-group>. <article-title>The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function</article-title>. <source>Cell Metab</source> (<year>2014</year>) <volume>20</volume>(<issue>1</issue>):<fpage>61</fpage>&#8211;<lpage>72</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cmet.2014.05.004</pub-id><pub-id pub-id-type="pmid">24930970</pub-id><pub-id pub-id-type="pmcid">PMC4079750</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Lao</surname><given-names>J</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W</given-names></name></person-group>. <article-title>Solute carrier family 35 member A2 (SLC35A2) is a prognostic biomarker and correlated with immune infiltration in stomach adenocarcinoma</article-title>. <source>PloS One</source> (<year>2023</year>) <volume>18</volume>(<issue>7</issue>):<elocation-id>e0287303</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0287303</pub-id><pub-id pub-id-type="pmid">37467193</pub-id><pub-id pub-id-type="pmcid">PMC10355401</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watson</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Vignali</surname><given-names>PDA</given-names></name><name name-style="western"><surname>Mullett</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Overacre-Delgoffe</surname><given-names>AE</given-names></name><name name-style="western"><surname>Peralta</surname><given-names>RM</given-names></name><name name-style="western"><surname>Grebinoski</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Metabolic support of tumour-infiltrating regulatory T cells by lactic acid</article-title>. <source>Nature</source> (<year>2021</year>) <volume>591</volume>(<issue>7851</issue>):<page-range>645&#8211;51</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-03045-2</pub-id><pub-id pub-id-type="pmcid">PMC7990682</pub-id><pub-id pub-id-type="pmid">33589820</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>T</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tong</surname><given-names>X</given-names></name></person-group>. <article-title>The role of the pentose phosphate pathway in diabetes and cancer</article-title>. <source>Front Endocrinol (Lausanne)</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>365</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fendo.2020.00365</pub-id><pub-id pub-id-type="pmid">32582032</pub-id><pub-id pub-id-type="pmcid">PMC7296058</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frauwirth</surname><given-names>KA</given-names></name><name name-style="western"><surname>Riley</surname><given-names>JL</given-names></name><name name-style="western"><surname>Harris</surname><given-names>MH</given-names></name><name name-style="western"><surname>Parry</surname><given-names>RV</given-names></name><name name-style="western"><surname>Rathmell</surname><given-names>JC</given-names></name><name name-style="western"><surname>Plas</surname><given-names>DR</given-names></name><etal/></person-group>. <article-title>The CD28 signaling pathway regulates glucose metabolism</article-title>. <source>Immunity</source> (<year>2002</year>) <volume>16</volume>(<issue>6</issue>):<page-range>769&#8211;77</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1074-7613(02)00323-0</pub-id><pub-id pub-id-type="pmid">12121659</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sukumar</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>M</given-names></name><name name-style="western"><surname>Crompton</surname><given-names>JG</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function</article-title>. <source>J Clin Invest</source> (<year>2013</year>) <volume>123</volume>(<issue>10</issue>):<page-range>4479&#8211;88</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1172/JCI69589</pub-id><pub-id pub-id-type="pmcid">PMC3784544</pub-id><pub-id pub-id-type="pmid">24091329</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>J</given-names></name><name name-style="western"><surname>Liao</surname><given-names>S</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>F</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Luo</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name></person-group>. <article-title>Effects of altered glycolysis levels on CD8(+) T cell activation and function</article-title>. <source>Cell Death Dis</source> (<year>2023</year>) <volume>14</volume>(<issue>7</issue>):<fpage>407</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41419-023-05937-3</pub-id><pub-id pub-id-type="pmid">37422501</pub-id><pub-id pub-id-type="pmcid">PMC10329707</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosios</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>VC</given-names></name><name name-style="western"><surname>Danai</surname><given-names>LV</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>MO</given-names></name><name name-style="western"><surname>Rathmell</surname><given-names>JC</given-names></name><name name-style="western"><surname>Steinhauser</surname><given-names>ML</given-names></name><etal/></person-group>. <article-title>Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells</article-title>. <source>Dev Cell</source> (<year>2016</year>) <volume>36</volume>(<issue>5</issue>):<page-range>540&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.devcel.2016.02.012</pub-id><pub-id pub-id-type="pmcid">PMC4766004</pub-id><pub-id pub-id-type="pmid">26954548</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reinfeld</surname><given-names>BI</given-names></name><name name-style="western"><surname>Madden</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>MM</given-names></name><name name-style="western"><surname>Chytil</surname><given-names>A</given-names></name><name name-style="western"><surname>Bader</surname><given-names>JE</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>AR</given-names></name><etal/></person-group>. <article-title>Cell-programmed nutrient partitioning in the tumour microenvironment</article-title>. <source>Nature</source> (<year>2021</year>) <volume>593</volume>(<issue>7858</issue>):<page-range>282&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-021-03442-1</pub-id><pub-id pub-id-type="pmcid">PMC8122068</pub-id><pub-id pub-id-type="pmid">33828302</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>CT</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YC</given-names></name><name name-style="western"><surname>Chi</surname><given-names>KK</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Arginine starvation kills tumor cells through aspartate exhaustion and mitochondrial dysfunction</article-title>. <source>Commun Biol</source> (<year>2018</year>) <volume>1</volume>:<elocation-id>178</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s42003-018-0178-4</pub-id><pub-id pub-id-type="pmid">30393775</pub-id><pub-id pub-id-type="pmcid">PMC6203837</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajaj</surname><given-names>E</given-names></name><name name-style="western"><surname>Sciacovelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Frezza</surname><given-names>C</given-names></name><name name-style="western"><surname>Erez</surname><given-names>A</given-names></name></person-group>. <article-title>The context-specific roles of urea cycle enzymes in tumorigenesis</article-title>. <source>Mol Cell</source> (<year>2021</year>) <volume>81</volume>(<issue>18</issue>):<page-range>3749&#8211;59</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.molcel.2021.08.005</pub-id><pub-id pub-id-type="pmid">34469752</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Missiaen</surname><given-names>R</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>NM</given-names></name><name name-style="western"><surname>Kim</surname><given-names>LC</given-names></name><name name-style="western"><surname>Nance</surname><given-names>B</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>M</given-names></name><name name-style="western"><surname>Skuli</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment</article-title>. <source>Cell Metab</source> (<year>2022</year>) <volume>34</volume>(<issue>8</issue>):<fpage>1151</fpage>&#8211;<lpage>1167.e7</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cmet.2022.06.010</pub-id><pub-id pub-id-type="pmid">35839757</pub-id><pub-id pub-id-type="pmcid">PMC9357184</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J</given-names></name><name name-style="western"><surname>Tan</surname><given-names>B</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name><name name-style="western"><surname>Bazer</surname><given-names>FW</given-names></name><etal/></person-group>. <article-title>Amino-acid transporters in T-cell activation and differentiation</article-title>. <source>Cell Death Dis</source> (<year>2017</year>) <volume>8</volume>(<issue>3</issue>):<fpage>e2655</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/cddis.2016.222</pub-id><pub-id pub-id-type="pmid">28252650</pub-id><pub-id pub-id-type="pmcid">PMC5386510</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geiger</surname><given-names>R</given-names></name><name name-style="western"><surname>Rieckmann</surname><given-names>JC</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>T</given-names></name><name name-style="western"><surname>Basso</surname><given-names>C</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fuhrer</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity</article-title>. <source>Cell</source> (<year>2016</year>) <volume>167</volume>(<issue>3</issue>):<fpage>829</fpage>&#8211;<lpage>842.e13</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2016.09.031</pub-id><pub-id pub-id-type="pmid">27745970</pub-id><pub-id pub-id-type="pmcid">PMC5075284</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Kremer</surname><given-names>DM</given-names></name><name name-style="western"><surname>Sajjakulnukit</surname><given-names>P</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Cancer SLC43A2 alters T cell methionine metabolism and histone methylation</article-title>. <source>Nature</source> (<year>2020</year>) <volume>585</volume>(<issue>7824</issue>):<page-range>277&#8211;82</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2682-1</pub-id><pub-id pub-id-type="pmcid">PMC7486248</pub-id><pub-id pub-id-type="pmid">32879489</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>EH</given-names></name><name name-style="western"><surname>Verway</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>RM</given-names></name><name name-style="western"><surname>Roy</surname><given-names>DG</given-names></name><name name-style="western"><surname>Steadman</surname><given-names>M</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Metabolic profiling using stable isotope tracing reveals distinct patterns of glucose utilization by physiologically activated CD8(+) T cells</article-title>. <source>Immunity</source> (<year>2019</year>) <volume>51</volume>(<issue>5</issue>):<fpage>856</fpage>&#8211;<lpage>870.e5</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2019.09.003</pub-id><pub-id pub-id-type="pmid">31747582</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>EH</given-names></name><name name-style="western"><surname>Verway</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>RM</given-names></name><name name-style="western"><surname>Roy</surname><given-names>DG</given-names></name><name name-style="western"><surname>Steadman</surname><given-names>M</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Serine is an essential metabolite for effector T cell expansion</article-title>. <source>Cell Metab</source> (<year>2017</year>) <volume>25</volume>(<issue>2</issue>):<page-range>345&#8211;57</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cmet.2016.12.011</pub-id><pub-id pub-id-type="pmid">28111214</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chatoff</surname><given-names>A</given-names></name><name name-style="western"><surname>Megill</surname><given-names>E</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Lysine catabolism reprograms tumour immunity through histone crotonylation</article-title>. <source>Nature</source> (<year>2023</year>) <volume>617</volume>(<issue>7962</issue>):<page-range>818&#8211;26</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-023-06061-0</pub-id><pub-id pub-id-type="pmcid">PMC11089809</pub-id><pub-id pub-id-type="pmid">37198486</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>H</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>NM</given-names></name><name name-style="western"><surname>Wen</surname><given-names>J</given-names></name><name name-style="western"><surname>Guy</surname><given-names>C</given-names></name><name name-style="western"><surname>Long</surname><given-names>L</given-names></name><name name-style="western"><surname>Dhungana</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Amino acids license kinase mTORC1 activity and treg cell function <italic toggle="yes">via</italic> small g proteins rag and rheb</article-title>. <source>Immunity</source> (<year>2019</year>) <volume>51</volume>(<issue>6</issue>):<fpage>1012</fpage>&#8211;<lpage>1027.e7</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2019.10.001</pub-id><pub-id pub-id-type="pmid">31668641</pub-id><pub-id pub-id-type="pmcid">PMC6948188</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Tao</surname><given-names>L</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name></person-group>. <article-title>Solute carrier transporters: the metabolic gatekeepers of immune cells</article-title>. <source>Acta Pharm Sin B</source> (<year>2020</year>) <volume>10</volume>(<issue>1</issue>):<fpage>61</fpage>&#8211;<lpage>78</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.apsb.2019.12.006</pub-id><pub-id pub-id-type="pmid">31993307</pub-id><pub-id pub-id-type="pmcid">PMC6977534</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X</given-names></name><name name-style="western"><surname>Dong</surname><given-names>W</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lv</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Tumor-repopulating cells induce PD-1 expression in CD8(+) T cells by transferring kynurenine and ahR activation</article-title>. <source>Cancer Cell</source> (<year>2018</year>) <volume>33</volume>(<issue>3</issue>):<fpage>480</fpage>&#8211;<lpage>494.e7</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ccell.2018.02.005</pub-id><pub-id pub-id-type="pmid">29533786</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minogue</surname><given-names>E</given-names></name><name name-style="western"><surname>Cunha</surname><given-names>PP</given-names></name><name name-style="western"><surname>Wadsworth</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Grice</surname><given-names>GL</given-names></name><name name-style="western"><surname>Sah-Teli</surname><given-names>SK</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Glutarate regulates T cell metabolism and anti-tumour immunity</article-title>. <source>Nat Metab</source> (<year>2023</year>) <volume>5</volume>(<issue>10</issue>):<page-range>1747&#8211;64</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s42255-023-00855-2</pub-id><pub-id pub-id-type="pmcid">PMC10590756</pub-id><pub-id pub-id-type="pmid">37605057</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group>. <article-title>Overview: lipid metabolism in the tumor microenvironment</article-title>. <source>Adv Exp Med Biol</source> (<year>2021</year>) <volume>1316</volume>:<page-range>41&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-981-33-6785-2_3</pub-id><pub-id pub-id-type="pmid">33740242</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Hartman</surname><given-names>CL</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Albert</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Si</surname><given-names>F</given-names></name><name name-style="western"><surname>Gao</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy</article-title>. <source>Sci Transl Med</source> (<year>2021</year>) <volume>13</volume>(<issue>587</issue>). doi:&#160;<pub-id pub-id-type="doi">10.1126/scitranslmed.aaz6314</pub-id><pub-id pub-id-type="pmcid">PMC12040281</pub-id><pub-id pub-id-type="pmid">33790024</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>C</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>LY</given-names></name><etal/></person-group>. <article-title>Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity</article-title>. <source>Cancer Cell</source> (<year>2023</year>) <volume>41</volume>(<issue>7</issue>):<fpage>1276</fpage>&#8211;<lpage>1293.e11</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ccell.2023.04.016</pub-id><pub-id pub-id-type="pmid">37244259</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saibil</surname><given-names>SD</given-names></name><name name-style="western"><surname>St Paul</surname><given-names>M</given-names></name><name name-style="western"><surname>Laister</surname><given-names>RC</given-names></name><name name-style="western"><surname>Garcia-Batres</surname><given-names>CR</given-names></name><name name-style="western"><surname>Israni-Winger</surname><given-names>K</given-names></name><name name-style="western"><surname>Elford</surname><given-names>AR</given-names></name><etal/></person-group>. <article-title>Activation of peroxisome proliferator-activated receptors &#945; and &#948; synergizes with inflammatory signals to enhance adoptive cell therapy</article-title>. <source>Cancer Res</source> (<year>2019</year>) <volume>79</volume>(<issue>3</issue>):<page-range>445&#8211;51</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-3053</pub-id><pub-id pub-id-type="pmid">30573521</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Yue</surname><given-names>C</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Egelston</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>STAT3 activation-induced fatty acid oxidation in CD8(+) t effector cells is critical for obesity-promoted breast tumor growth</article-title>. <source>Cell Metab</source> (<year>2020</year>) <volume>31</volume>(<issue>1</issue>):<fpage>148</fpage>&#8211;<lpage>161.e5</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cmet.2019.10.013</pub-id><pub-id pub-id-type="pmid">31761565</pub-id><pub-id pub-id-type="pmcid">PMC6949402</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chapman</surname><given-names>NM</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>H</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>TM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>P</given-names></name><name name-style="western"><surname>Dhungana</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>mTOR coordinates transcriptional programs and mitochondrial metabolism of activated t(reg) subsets to protect tissue homeostasis</article-title>. <source>Nat Commun</source> (<year>2018</year>) <volume>9</volume>(<issue>1</issue>):<fpage>2095</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-018-04392-5</pub-id><pub-id pub-id-type="pmid">29844370</pub-id><pub-id pub-id-type="pmcid">PMC5974344</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinberg</surname><given-names>SE</given-names></name><name name-style="western"><surname>Singer</surname><given-names>BD</given-names></name><name name-style="western"><surname>Steinert</surname><given-names>EM</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>CA</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>MM</given-names></name><name name-style="western"><surname>Mart&#237;nez-Reyes</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Mitochondrial complex III is essential for suppressive function of regulatory T cells</article-title>. <source>Nature</source> (<year>2019</year>) <volume>565</volume>(<issue>7740</issue>):<page-range>495&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-018-0846-z</pub-id><pub-id pub-id-type="pmcid">PMC6345596</pub-id><pub-id pub-id-type="pmid">30626970</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name><name name-style="western"><surname>Dean</surname><given-names>JW</given-names></name><name name-style="western"><surname>Bostick</surname><given-names>JW</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>SE</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Requirement of mitochondrial transcription factor a in tissueresident regulatory T cell maintenance and function</article-title>. <source>Cell Rep</source> (<year>2019</year>) <volume>28</volume>(<issue>1</issue>):<fpage>159</fpage>&#8211;<lpage>171.e4</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.celrep.2019.06.024</pub-id><pub-id pub-id-type="pmid">31269437</pub-id><pub-id pub-id-type="pmcid">PMC6679941</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saravia</surname><given-names>J</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>H</given-names></name><name name-style="western"><surname>Dhungana</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bastardo Blanco</surname><given-names>D</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>TM</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>NM</given-names></name><etal/></person-group>. <article-title>Homeostasis and transitional activation of regulatory T cells require c-myc</article-title>. <source>Sci Adv</source> (<year>2020</year>) <volume>6</volume>(<issue>1</issue>):<elocation-id>eaaw6443</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1126/sciadv.aaw6443</pub-id><pub-id pub-id-type="pmid">31911938</pub-id><pub-id pub-id-type="pmcid">PMC6938709</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raud</surname><given-names>B</given-names></name><name name-style="western"><surname>Roy</surname><given-names>DG</given-names></name><name name-style="western"><surname>Divakaruni</surname><given-names>AS</given-names></name><name name-style="western"><surname>Tarasenko</surname><given-names>TN</given-names></name><name name-style="western"><surname>Franke</surname><given-names>R</given-names></name><name name-style="western"><surname>Ma</surname><given-names>EH</given-names></name><etal/></person-group>. <article-title>Etomoxir actions on regulatory and memory T cells are independent of cpt1a-mediated fatty acid oxidation</article-title>. <source>Cell Metab</source> (<year>2018</year>) <volume>28</volume>(<issue>3</issue>):<fpage>504</fpage>&#8211;<lpage>515.e7</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cmet.2018.06.002</pub-id><pub-id pub-id-type="pmid">30043753</pub-id><pub-id pub-id-type="pmcid">PMC6747686</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>H</given-names></name></person-group>. <article-title>Lipid metabolism reprogramming of CD8(+) T cell and therapeutic implications in cancer</article-title>. <source>Cancer Lett</source> (<year>2023</year>) <volume>567</volume>:<elocation-id>216267</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.canlet.2023.216267</pub-id><pub-id pub-id-type="pmid">37315709</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism</article-title>. <source>Nature</source> (<year>2016</year>) <volume>531</volume>(<issue>7596</issue>):<page-range>651&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nature17412</pub-id><pub-id pub-id-type="pmcid">PMC4851431</pub-id><pub-id pub-id-type="pmid">26982734</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>J</given-names></name><name name-style="western"><surname>Shan</surname><given-names>C</given-names></name><name name-style="western"><surname>Kang</surname><given-names>HB</given-names></name><name name-style="western"><surname>Elf</surname><given-names>S</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex</article-title>. <source>Mol Cell</source> (<year>2014</year>) <volume>53</volume>(<issue>4</issue>):<page-range>534&#8211;48</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.molcel.2013.12.026</pub-id><pub-id pub-id-type="pmcid">PMC3943932</pub-id><pub-id pub-id-type="pmid">24486017</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachem</surname><given-names>A</given-names></name><name name-style="western"><surname>Makhlouf</surname><given-names>C</given-names></name><name name-style="western"><surname>Binger</surname><given-names>KJ</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>DP</given-names></name><name name-style="western"><surname>Tull</surname><given-names>D</given-names></name><name name-style="western"><surname>Hochheiser</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8(+) T cells</article-title>. <source>Immunity</source> (<year>2019</year>) <volume>51</volume>(<issue>2</issue>):<fpage>285</fpage>&#8211;<lpage>297.e5</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2019.06.002</pub-id><pub-id pub-id-type="pmid">31272808</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>NM</given-names></name><name name-style="western"><surname>Geiger</surname><given-names>TL</given-names></name><name name-style="western"><surname>Chi</surname><given-names>H</given-names></name></person-group>. <article-title>T cell metabolism in homeostasis and cancer immunity</article-title>. <source>Curr Opin Biotechnol</source> (<year>2021</year>) <volume>68</volume>:<page-range>240&#8211;50</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.copbio.2021.02.003</pub-id><pub-id pub-id-type="pmcid">PMC8137568</pub-id><pub-id pub-id-type="pmid">33676144</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>AR</given-names></name><name name-style="western"><surname>Rathmell</surname><given-names>WK</given-names></name><name name-style="western"><surname>Rathmell</surname><given-names>JC</given-names></name></person-group>. <article-title>The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy</article-title>. <source>Elife</source> (<year>2020</year>) <volume>9</volume>:<elocation-id>e55185</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.7554/eLife.55185</pub-id><pub-id pub-id-type="pmid">32367803</pub-id><pub-id pub-id-type="pmcid">PMC7200151</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phan</surname><given-names>AT</given-names></name><name name-style="western"><surname>Goldrath</surname><given-names>AW</given-names></name></person-group>. <article-title>Hypoxia-inducible factors regulate T cell metabolism and function</article-title>. <source>Mol Immunol</source> (<year>2015</year>) <volume>68</volume>(<issue>2 Pt C</issue>):<page-range>527&#8211;35</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.molimm.2015.08.004</pub-id><pub-id pub-id-type="pmcid">PMC4679538</pub-id><pub-id pub-id-type="pmid">26298577</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oestreich</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Read</surname><given-names>KA</given-names></name><name name-style="western"><surname>Gilbertson</surname><given-names>SE</given-names></name><name name-style="western"><surname>Hough</surname><given-names>KP</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>PW</given-names></name><name name-style="western"><surname>Krishnamoorthy</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Bcl-6 directly represses the gene program of the glycolysis pathway</article-title>. <source>Nat Immunol</source> (<year>2014</year>) <volume>15</volume>(<issue>10</issue>):<page-range>957&#8211;64</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ni.2985</pub-id><pub-id pub-id-type="pmcid">PMC4226759</pub-id><pub-id pub-id-type="pmid">25194422</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mascanfroni</surname><given-names>ID</given-names></name><name name-style="western"><surname>Takenaka</surname><given-names>MC</given-names></name><name name-style="western"><surname>Yeste</surname><given-names>A</given-names></name><name name-style="western"><surname>Patel</surname><given-names>B</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kenison</surname><given-names>JE</given-names></name><etal/></person-group>. <article-title>Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-a</article-title>. <source>Nat Med</source> (<year>2015</year>) <volume>21</volume>(<issue>6</issue>):<page-range>638&#8211;46</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nm.3868</pub-id><pub-id pub-id-type="pmcid">PMC4476246</pub-id><pub-id pub-id-type="pmid">26005855</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finlay</surname><given-names>DK</given-names></name><name name-style="western"><surname>Rosenzweig</surname><given-names>E</given-names></name><name name-style="western"><surname>Sinclair</surname><given-names>LV</given-names></name><name name-style="western"><surname>Feijoo-Carnero</surname><given-names>C</given-names></name><name name-style="western"><surname>Hukelmann</surname><given-names>JL</given-names></name><name name-style="western"><surname>Rolf</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>PDK1 regulation of mTOR and hypoxia-inducible factor 1integrate metabolism and migration of CD8+ T cells</article-title>. <source>J Exp Med</source> (<year>2012</year>) <volume>209</volume>(<issue>13</issue>):<page-range>2441&#8211;53</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1084/jem.20112607</pub-id><pub-id pub-id-type="pmcid">PMC3526360</pub-id><pub-id pub-id-type="pmid">23183047</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gropper</surname><given-names>Y</given-names></name><name name-style="western"><surname>Feferman</surname><given-names>T</given-names></name><name name-style="western"><surname>Shalit</surname><given-names>T</given-names></name><name name-style="western"><surname>Salame</surname><given-names>TM</given-names></name><name name-style="western"><surname>Porat</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shakhar</surname><given-names>G</given-names></name></person-group>. <article-title>Culturing CTLs under hypoxic conditions enhances their cytolysis and improves their anti-tumor function</article-title>. <source>Cell Rep</source> (<year>2017</year>) <volume>20</volume>(<issue>11</issue>):<page-range>2547&#8211;55</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.celrep.2017.08.071</pub-id><pub-id pub-id-type="pmid">28903036</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kukita</surname><given-names>K</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Kajiwara</surname><given-names>T</given-names></name><name name-style="western"><surname>Kutomi</surname><given-names>G</given-names></name><name name-style="western"><surname>Saito</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Cancer-associated oxidase ERO1-a regulates the expression of MHC class i molecule <italic toggle="yes">via</italic> oxidative folding</article-title>. <source>J Immunol</source> (<year>2015</year>) <volume>194</volume>(<issue>10</issue>):<page-range>4988&#8211;96</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1303228</pub-id><pub-id pub-id-type="pmid">25870246</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>K</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>P</given-names></name><name name-style="western"><surname>Voelkl</surname><given-names>S</given-names></name><name name-style="western"><surname>Meidenbauer</surname><given-names>N</given-names></name><name name-style="western"><surname>Ammer</surname><given-names>J</given-names></name><name name-style="western"><surname>Edinger</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Inhibitory effect of tumor cell-derived lactic acid on human T cells</article-title>. <source>Blood</source> (<year>2007</year>) <volume>109</volume>(<issue>9</issue>):<page-range>3812&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1182/blood-2006-07-035972</pub-id><pub-id pub-id-type="pmid">17255361</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haas</surname><given-names>R</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J</given-names></name><name name-style="western"><surname>Rocher-Ros</surname><given-names>V</given-names></name><name name-style="western"><surname>Nadkarni</surname><given-names>S</given-names></name><name name-style="western"><surname>Montero-Melendez</surname><given-names>T</given-names></name><name name-style="western"><surname>D'Acquisto</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and effector functions</article-title>. <source>PloS Biol</source> (<year>2015</year>) <volume>13</volume>(<issue>7</issue>):<elocation-id>e1002202</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pbio.1002202</pub-id><pub-id pub-id-type="pmid">26181372</pub-id><pub-id pub-id-type="pmcid">PMC4504715</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aggarwal</surname><given-names>A</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>S</given-names></name><name name-style="western"><surname>Misra</surname><given-names>R</given-names></name></person-group>. <article-title>Chemokine and chemokine receptor analysis reveals elevated interferon-inducible protein-10 (IP)-10/CXCL10 levels and increased number of CCR5+ and CXCR3+ CD4 T cells in synovial fluid of patients with enthesitis-related arthritis (ERA)</article-title>. <source>Clin Exp Immunol</source> (<year>2007</year>) <volume>148</volume>(<issue>3</issue>):<page-range>515&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1365-2249.2007.03377.x</pub-id><pub-id pub-id-type="pmcid">PMC1941930</pub-id><pub-id pub-id-type="pmid">17374135</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>J</given-names></name><name name-style="western"><surname>Gong</surname><given-names>ZC</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>YN</given-names></name><name name-style="western"><surname>Wu</surname><given-names>HH</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LT</given-names></name><etal/></person-group>. <article-title>Lactic acid promotes metastatic niche formation in bone metastasis of colorectal cancer</article-title>. <source>Cell Commun Signal</source> (<year>2021</year>) <volume>19</volume>(<issue>1</issue>):<elocation-id>9</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12964-020-00667-x</pub-id><pub-id pub-id-type="pmid">33478523</pub-id><pub-id pub-id-type="pmcid">PMC7818572</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A</given-names></name><name name-style="western"><surname>Nayak</surname><given-names>N</given-names></name><name name-style="western"><surname>Rathi</surname><given-names>P</given-names></name><name name-style="western"><surname>Verma</surname><given-names>D</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Microbiome and host crosstalk: A new paradigm to cancer therapy</article-title>. <source>Semin Cancer Biol</source> (<year>2021</year>) <volume>70</volume>:<fpage>71</fpage>&#8211;<lpage>84</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.semcancer.2020.05.014</pub-id><pub-id pub-id-type="pmid">32479952</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanoue</surname><given-names>T</given-names></name><name name-style="western"><surname>Morita</surname><given-names>S</given-names></name><name name-style="western"><surname>Plichta</surname><given-names>DR</given-names></name><name name-style="western"><surname>Skelly</surname><given-names>AN</given-names></name><name name-style="western"><surname>Suda</surname><given-names>W</given-names></name><name name-style="western"><surname>Sugiura</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>A defined commensal consortium elicits CD8 T cells and anticancer immunity</article-title>. <source>Nature</source> (<year>2019</year>) <volume>565</volume>(<issue>7741</issue>):<page-range>600&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-019-0878-z</pub-id><pub-id pub-id-type="pmid">30675064</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cremonesi</surname><given-names>E</given-names></name><name name-style="western"><surname>Governa</surname><given-names>V</given-names></name><name name-style="western"><surname>Garzon</surname><given-names>JFG</given-names></name><name name-style="western"><surname>Mele</surname><given-names>V</given-names></name><name name-style="western"><surname>Amicarella</surname><given-names>F</given-names></name><name name-style="western"><surname>Muraro</surname><given-names>MG</given-names></name><etal/></person-group>. <article-title>Gut microbiota modulate T cell trafficking into human colorectal cancer</article-title>. <source>Gut</source> (<year>2018</year>) <volume>67</volume>(<issue>11</issue>):<page-range>1984&#8211;94</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1136/gutjnl-2016-313498</pub-id><pub-id pub-id-type="pmid">29437871</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lop&#232;s</surname><given-names>A</given-names></name><name name-style="western"><surname>Billard</surname><given-names>E</given-names></name><name name-style="western"><surname>Casse</surname><given-names>AH</given-names></name><name name-style="western"><surname>Vill&#233;ger</surname><given-names>R</given-names></name><name name-style="western"><surname>Veziant</surname><given-names>J</given-names></name><name name-style="western"><surname>Roche</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Colibactin-positive escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer</article-title>. <source>Int J Cancer</source> (<year>2020</year>) <volume>146</volume>(<issue>11</issue>):<page-range>3147&#8211;59</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ijc.32920</pub-id><pub-id pub-id-type="pmid">32037530</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Luo</surname><given-names>L</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Q</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name><name name-style="western"><surname>Rush</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Bifidobacterium alters the gut microbiota and modulates the functional metabolism of t regulatory cells in the context of immune checkpoint blockade</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2020</year>) <volume>117</volume>(<issue>44</issue>):<page-range>27509&#8211;15</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.1921223117</pub-id><pub-id pub-id-type="pmcid">PMC7959554</pub-id><pub-id pub-id-type="pmid">33077598</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicholson</surname><given-names>JK</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>E</given-names></name><name name-style="western"><surname>Kinross</surname><given-names>J</given-names></name><name name-style="western"><surname>Burcelin</surname><given-names>R</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>G</given-names></name><name name-style="western"><surname>Jia</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Host-gut microbiota metabolic interactions</article-title>. <source>Science</source> (<year>2012</year>) <volume>336</volume>(<issue>6086</issue>):<page-range>1262&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.1223813</pub-id><pub-id pub-id-type="pmid">22674330</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brestoff</surname><given-names>JR</given-names></name><name name-style="western"><surname>Artis</surname><given-names>D</given-names></name></person-group>. <article-title>Commensal bacteria at the interface of host metabolism and the immune system</article-title>. <source>Nat Immunol</source> (<year>2013</year>) <volume>14</volume>(<issue>7</issue>):<page-range>676&#8211;84</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ni.2640</pub-id><pub-id pub-id-type="pmcid">PMC4013146</pub-id><pub-id pub-id-type="pmid">23778795</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Oh</surname><given-names>SF</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Microbial bile acid metabolites modulate gut RORg(+) regulatory T cell homeostasis</article-title>. <source>Nature</source> (<year>2020</year>) <volume>577</volume>(<issue>7790</issue>):<page-range>410&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-019-1865-0</pub-id><pub-id pub-id-type="pmcid">PMC7274525</pub-id><pub-id pub-id-type="pmid">31875848</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hang</surname><given-names>S</given-names></name><name name-style="western"><surname>Paik</surname><given-names>D</given-names></name><name name-style="western"><surname>Yao</surname><given-names>L</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E</given-names></name><name name-style="western"><surname>Trinath</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Bile acid metabolites control T(H)17 and t(reg) cell differentiation</article-title>. <source>Nature</source> (<year>2019</year>) <volume>576</volume>(<issue>7785</issue>):<page-range>143&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-019-1785-z</pub-id><pub-id pub-id-type="pmcid">PMC6949019</pub-id><pub-id pub-id-type="pmid">31776512</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>C</given-names></name><name name-style="western"><surname>McKenney</surname><given-names>PT</given-names></name><name name-style="western"><surname>Konstantinovsky</surname><given-names>D</given-names></name><name name-style="western"><surname>Isaeva</surname><given-names>OI</given-names></name><name name-style="western"><surname>Schizas</surname><given-names>M</given-names></name><name name-style="western"><surname>Verter</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells</article-title>. <source>Nature</source> (<year>2020</year>) <volume>581</volume>(<issue>7809</issue>):<page-range>475&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2193-0</pub-id><pub-id pub-id-type="pmcid">PMC7540721</pub-id><pub-id pub-id-type="pmid">32461639</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M</given-names></name><name name-style="western"><surname>Kang</surname><given-names>SG</given-names></name><name name-style="western"><surname>Jannasch</surname><given-names>AH</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>B</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway</article-title>. <source>Mucosal Immunol</source> (<year>2015</year>) <volume>8</volume>(<issue>1</issue>):<fpage>80</fpage>&#8211;<lpage>93</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/mi.2014.44</pub-id><pub-id pub-id-type="pmid">24917457</pub-id><pub-id pub-id-type="pmcid">PMC4263689</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>L</given-names></name><name name-style="western"><surname>Lv</surname><given-names>P</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name></person-group>. <article-title>Treatment with butyrate alleviates dextran sulfate sodium and clostridium difficile-induced colitis by preventing activity of Th17 cells <italic toggle="yes">via</italic> regulation of SIRT1/mTOR in mice</article-title>. <source>J Nutr Biochem</source> (<year>2023</year>) <volume>111</volume>:<elocation-id>109155</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jnutbio.2022.109155</pub-id><pub-id pub-id-type="pmid">36162566</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luu</surname><given-names>M</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>K</given-names></name><name name-style="western"><surname>Wedi</surname><given-names>F</given-names></name><name name-style="western"><surname>Breidenbend</surname><given-names>C</given-names></name><name name-style="western"><surname>Leister</surname><given-names>H</given-names></name><name name-style="western"><surname>Pautz</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Regulation of the effector function of CD8(+) T cells by gut microbiota-derived metabolite butyrate</article-title>. <source>Sci Rep</source> (<year>2018</year>) <volume>8</volume>(<issue>1</issue>):<fpage>14430</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-018-32860-x</pub-id><pub-id pub-id-type="pmid">30258117</pub-id><pub-id pub-id-type="pmcid">PMC6158259</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luu</surname><given-names>M</given-names></name><name name-style="western"><surname>Pautz</surname><given-names>S</given-names></name><name name-style="western"><surname>Kohl</surname><given-names>V</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R</given-names></name><name name-style="western"><surname>Romero</surname><given-names>R</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes</article-title>. <source>Nat Commun</source> (<year>2019</year>) <volume>10</volume>(<issue>1</issue>):<fpage>760</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-019-08711-2</pub-id><pub-id pub-id-type="pmid">30770822</pub-id><pub-id pub-id-type="pmcid">PMC6377655</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brand</surname><given-names>A</given-names></name><name name-style="western"><surname>Singer</surname><given-names>K</given-names></name><name name-style="western"><surname>Koehl</surname><given-names>GE</given-names></name><name name-style="western"><surname>Kolitzus</surname><given-names>M</given-names></name><name name-style="western"><surname>Schoenhammer</surname><given-names>G</given-names></name><name name-style="western"><surname>Thiel</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>LDHA-associated lactic acid production blunts tumor immunosurveillance by t and NK cells</article-title>. <source>Cell Metab</source> (<year>2016</year>) <volume>24</volume>(<issue>5</issue>):<page-range>657&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cmet.2016.08.011</pub-id><pub-id pub-id-type="pmid">27641098</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Lactate increases stemness of CD8 + T cells to augment antitumor immunity</article-title>. <source>Nat Commun</source> (<year>2022</year>) <volume>13</volume>(<issue>1</issue>):<fpage>4981</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-022-32521-8</pub-id><pub-id pub-id-type="pmid">36068198</pub-id><pub-id pub-id-type="pmcid">PMC9448806</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumagai</surname><given-names>S</given-names></name><name name-style="western"><surname>Koyama</surname><given-names>S</given-names></name><name name-style="western"><surname>Itahashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Tanegashima</surname><given-names>T</given-names></name><name name-style="western"><surname>Lin</surname><given-names>YT</given-names></name><name name-style="western"><surname>Togashi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments</article-title>. <source>Cancer Cell</source> (<year>2022</year>) <volume>40</volume>(<issue>2</issue>):<fpage>201</fpage>&#8211;<lpage>218.e9</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ccell.2022.01.001</pub-id><pub-id pub-id-type="pmid">35090594</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yin</surname><given-names>T</given-names></name><name name-style="western"><surname>Lu</surname><given-names>XJ</given-names></name></person-group>. <article-title>T cell dysfunction in cancer immunity and immunotherapy</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>1719</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.01719</pub-id><pub-id pub-id-type="pmid">31379886</pub-id><pub-id pub-id-type="pmcid">PMC6659036</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khair</surname><given-names>DO</given-names></name><name name-style="western"><surname>Bax</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Mele</surname><given-names>S</given-names></name><name name-style="western"><surname>Crescioli</surname><given-names>S</given-names></name><name name-style="western"><surname>Pellizzari</surname><given-names>G</given-names></name><name name-style="western"><surname>Khiabany</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>453</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00453</pub-id><pub-id pub-id-type="pmid">30941125</pub-id><pub-id pub-id-type="pmcid">PMC6435047</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardoll</surname><given-names>DM</given-names></name></person-group>. <article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title>. <source>Nat Rev Cancer</source> (<year>2012</year>) <volume>12</volume>(<issue>4</issue>):<page-range>252&#8211;64</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrc3239</pub-id><pub-id pub-id-type="pmcid">PMC4856023</pub-id><pub-id pub-id-type="pmid">22437870</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basile</surname><given-names>D</given-names></name><name name-style="western"><surname>Garattini</surname><given-names>SK</given-names></name><name name-style="western"><surname>Bonotto</surname><given-names>M</given-names></name><name name-style="western"><surname>Ongaro</surname><given-names>E</given-names></name><name name-style="western"><surname>Casagrande</surname><given-names>M</given-names></name><name name-style="western"><surname>Cattaneo</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Immunotherapy for colorectal cancer: where are we heading</article-title>? <source>Expert Opin Biol Ther</source> (<year>2017</year>) <volume>17</volume>(<issue>6</issue>):<page-range>709&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/14712598.2017.1315405</pub-id><pub-id pub-id-type="pmid">28375039</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Payandeh</surname><given-names>Z</given-names></name><name name-style="western"><surname>Khalili</surname><given-names>S</given-names></name><name name-style="western"><surname>Somi</surname><given-names>MH</given-names></name><name name-style="western"><surname>Mard-Soltani</surname><given-names>M</given-names></name><name name-style="western"><surname>Baghbanzadeh</surname><given-names>A</given-names></name><name name-style="western"><surname>Hajiasgharzadeh</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>PD-1/PD-L1-dependent immune response in colorectal cancer</article-title>. <source>J Cell Physiol</source> (<year>2020</year>) <volume>235</volume>(<issue>7-8</issue>):<page-range>5461&#8211;75</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/jcp.29494</pub-id><pub-id pub-id-type="pmid">31960962</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>DT</given-names></name><name name-style="western"><surname>Uram</surname><given-names>JN</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>BR</given-names></name><name name-style="western"><surname>Kemberling</surname><given-names>H</given-names></name><name name-style="western"><surname>Eyring</surname><given-names>AD</given-names></name><etal/></person-group>. <article-title>PD-1 blockade in tumors with mismatch-repair deficiency</article-title>. <source>N Engl J Med</source> (<year>2015</year>) <volume>372</volume>(<issue>26</issue>):<page-range>2509&#8211;20</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1500596</pub-id><pub-id pub-id-type="pmcid">PMC4481136</pub-id><pub-id pub-id-type="pmid">26028255</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boland</surname><given-names>PM</given-names></name><name name-style="western"><surname>Ma</surname><given-names>WW</given-names></name></person-group>. Erratum: Boland, P.M., et al.<article-title>Immunotherapy for colorectal cancer, cancers 2017, 9, 50</article-title>. <source>Cancers (Basel)</source> (<year>2020</year>) <volume>12</volume>(<issue>5</issue>):<elocation-id>1320</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/cancers12051320</pub-id><pub-id pub-id-type="pmid">32455912</pub-id><pub-id pub-id-type="pmcid">PMC7281758</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patsoukis</surname><given-names>N</given-names></name><name name-style="western"><surname>Bardhan</surname><given-names>K</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>P</given-names></name><name name-style="western"><surname>Sari</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Bell</surname><given-names>LN</given-names></name><etal/></person-group>. <article-title>PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation</article-title>. <source>Nat Commun</source> (<year>2015</year>) <volume>6</volume>:<fpage>6692</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ncomms7692</pub-id><pub-id pub-id-type="pmid">25809635</pub-id><pub-id pub-id-type="pmcid">PMC4389235</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name></person-group>. <article-title>Manipulating T-cell metabolism to enhance immunotherapy in solid tumor</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>1090429</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1090429</pub-id><pub-id pub-id-type="pmid">36618408</pub-id><pub-id pub-id-type="pmcid">PMC9812959</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chowdhury</surname><given-names>PS</given-names></name><name name-style="western"><surname>Chamoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Honjo</surname><given-names>T</given-names></name></person-group>. <article-title>PPAR-induced fatty acid oxidation in T cells increases the number of tumor-reactive CD8(+) T cells and facilitates anti-PD-1 therapy</article-title>. <source>Cancer Immunol Res</source> (<year>2018</year>) <volume>6</volume>(<issue>11</issue>):<page-range>1375&#8211;87</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-18-0095</pub-id><pub-id pub-id-type="pmid">30143538</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martino</surname><given-names>M</given-names></name><name name-style="western"><surname>Naso</surname><given-names>V</given-names></name><name name-style="western"><surname>Loteta</surname><given-names>B</given-names></name><name name-style="western"><surname>Canale</surname><given-names>FA</given-names></name><name name-style="western"><surname>Pugliese</surname><given-names>M</given-names></name><name name-style="western"><surname>Alati</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Chimeric antigen receptor T-cell therapy: what we expect soon</article-title>. <source>Int J Mol Sci</source> (<year>2022</year>) <volume>23</volume>(<issue>21</issue>):<elocation-id>13332</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijms232113332</pub-id><pub-id pub-id-type="pmid">36362130</pub-id><pub-id pub-id-type="pmcid">PMC9657035</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsimberidou</surname><given-names>AM</given-names></name><name name-style="western"><surname>Van Morris</surname><given-names>K</given-names></name><name name-style="western"><surname>Vo</surname><given-names>HH</given-names></name><name name-style="western"><surname>Eck</surname><given-names>S</given-names></name><name name-style="western"><surname>Lin</surname><given-names>YF</given-names></name><name name-style="western"><surname>Rivas</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors</article-title>. <source>J Hematol Oncol</source> (<year>2021</year>) <volume>14</volume>(<issue>1</issue>):<fpage>102</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13045-021-01115-0</pub-id><pub-id pub-id-type="pmid">34193217</pub-id><pub-id pub-id-type="pmcid">PMC8243554</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newick</surname><given-names>K</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>S</given-names></name><name name-style="western"><surname>Moon</surname><given-names>E</given-names></name><name name-style="western"><surname>Albelda</surname><given-names>SM</given-names></name></person-group>. <article-title>CAR T cell therapy for solid tumors</article-title>. <source>Annu Rev Med</source> (<year>2017</year>) <volume>68</volume>:<page-range>139&#8211;52</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1146/annurev-med-062315-120245</pub-id><pub-id pub-id-type="pmid">27860544</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name></person-group>. <article-title>CAR-T cell therapy in hematological malignancies: current opportunities and challenges</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>927153</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.927153</pub-id><pub-id pub-id-type="pmid">35757715</pub-id><pub-id pub-id-type="pmcid">PMC9226391</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>H</given-names></name></person-group>. <article-title>Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies</article-title>. <source>Int Immunol</source> (<year>2021</year>) <volume>33</volume>(<issue>11</issue>):<page-range>551&#8211;62</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/intimm/dxab052</pub-id><pub-id pub-id-type="pmid">34374779</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group>. <article-title>TCR engineered T cells for solid tumor immunotherapy</article-title>. <source>Exp Hematol Oncol</source> (<year>2022</year>) <volume>11</volume>(<issue>1</issue>):<fpage>38</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s40164-022-00291-0</pub-id><pub-id pub-id-type="pmid">35725570</pub-id><pub-id pub-id-type="pmcid">PMC9210724</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salazar</surname><given-names>G</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>A</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Serino</surname><given-names>A</given-names></name><name name-style="western"><surname>Hilenski</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>SQSTM1/p62 and PPARGC1A/PGC-1alpha at the interface of autophagy and vascular senescence</article-title>. <source>Autophagy</source> (<year>2020</year>) <volume>16</volume>(<issue>6</issue>):<page-range>1092&#8211;110</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/15548627.2019.1659612</pub-id><pub-id pub-id-type="pmcid">PMC7469683</pub-id><pub-id pub-id-type="pmid">31441382</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scharping</surname><given-names>NE</given-names></name><name name-style="western"><surname>Menk</surname><given-names>AV</given-names></name><name name-style="western"><surname>Moreci</surname><given-names>RS</given-names></name><name name-style="western"><surname>Whetstone</surname><given-names>RD</given-names></name><name name-style="western"><surname>Dadey</surname><given-names>RE</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>SC</given-names></name><etal/></person-group>. <article-title>The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction</article-title>. <source>Immunity</source> (<year>2016</year>) <volume>45</volume>(<issue>2</issue>):<page-range>374&#8211;88</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2016.07.009</pub-id><pub-id pub-id-type="pmcid">PMC5207350</pub-id><pub-id pub-id-type="pmid">27496732</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>KDM3A senses oxygen availability to regulate PGC-1&#945;-mediated mitochondrial biogenesis</article-title>. <source>Mol Cell</source> (<year>2019</year>) <volume>76</volume>(<issue>6</issue>):<fpage>885</fpage>&#8211;<lpage>895.e7</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.molcel.2019.09.019</pub-id><pub-id pub-id-type="pmid">31629659</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>M</given-names></name><name name-style="western"><surname>Niu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ge</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Combination of oral STING agonist MSA-2 and anti-TGF-&#946;/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors</article-title>. <source>J Hematol Oncol</source> (<year>2022</year>) <volume>15</volume>(<issue>1</issue>):<fpage>142</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13045-022-01363-8</pub-id><pub-id pub-id-type="pmid">36209176</pub-id><pub-id pub-id-type="pmcid">PMC9548169</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Niu</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Anti-TGF-&#946;/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer</article-title>. <source>J Immunother Cancer</source> (<year>2022</year>) <volume>10</volume>(<issue>12</issue>):<elocation-id>e005543</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1136/jitc-2022-005543</pub-id><pub-id pub-id-type="pmid">36460337</pub-id><pub-id pub-id-type="pmcid">PMC9723957</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>